Multi-targeting compound and use thereof
By developing multi-targeting compounds that simultaneously target FAP, CXCR4, αvβ3, or GRPR receptors, the problem of poor sensitivity and therapeutic efficacy of existing probes in tumor diagnosis has been solved, achieving more efficient tumor cell targeting and uptake, and is applicable to the diagnosis and treatment of diseases with multiple abnormally expressed receptors.
Patent Information
- Application Number
- PCT/CN2024/093514
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-05-15
- Filing Date
- 2024-05-15
- Publication Date
- 2024-11-21
AI Technical Summary
Existing radionuclide-labeled probes have problems with poor sensitivity and treatment efficacy in tumor diagnosis, especially due to insufficient diagnostic accuracy caused by the heterogeneity and inhomogeneity of receptors on the surface of tumor cells.
Develop a multi-targeting compound that can simultaneously target FAP, CXCR4, αvβ3, or GRPR receptors, thereby enhancing the targeting and uptake efficiency of tumor cells by binding to multiple receptors.
It increases the number and utilization efficiency of receptors for tumor cells, enhances the specific targeting and uptake efficiency of tumors, and reduces the clearance time of non-tumor tissues. It is suitable for the diagnosis and treatment of diseases characterized by abnormal expression of FAP, CXCR4, GRPR or αvβ3.
Smart Images

Figure PCTCN2024093514-FTAPPB-I100001 
Figure PCTCN2024093514-FTAPPB-I100002 
Figure PCTCN2024093514-FTAPPB-I100003
Abstract
Description
Multi-target compounds and their applications
[0001] CROSS-REFERENCE TO RELATED APPLICATIONS
[0002] This application claims priority to three Chinese patent applications with application numbers 2023105464618, 2023105464514, and 2023105456931 filed on May 15, 2023, the entire contents of which are incorporated herein by reference in their entirety. Technical Field
[0003] The present invention relates to a multi-target compound, a pharmaceutical composition comprising or consisting of the compound, a kit comprising or consisting of the compound or pharmaceutical composition, and use of the compound or pharmaceutical composition in diagnosing or treating diseases. Background Art
[0004] Fibroblast activation protein (FAP) is a membrane serine peptidase expressed on the surface of activated fibroblasts in the tumor stroma and plays a crucial role in tumor development and progression. Previous studies have shown that FAP is generally not expressed in normal human tissues but is selectively and highly expressed on the surface of stromal fibroblasts in over 90% of epithelial malignancies, including breast, ovarian, lung, colorectal, gastric, and pancreatic cancers. Given its widespread expression and crucial role in tumors, FAP has become an important target for tumor imaging and treatment.
[0005] CXC chemokine receptor type 4 (CXCR4), also known as fusin or cluster of differentiation 184 (CD184), is a seven-transmembrane G protein-coupled receptor (GPCR) belonging to the class I or rhodopsin-like GPCR family. Under normal physiological conditions, CXCR4 plays multiple roles and is primarily expressed in the hematopoietic and immune systems. CXCR4 was initially discovered as a coreceptor involved in human immunodeficiency virus (HIV) cell entry. Subsequent studies have shown its expression in many tissues, including the brain, thymus, lymphoid tissues, spleen, stomach, and small intestine, as well as in specific cell types such as hematopoietic stem cells (HSCs), mature lymphocytes, and fibroblasts. CXCL12, previously named SDF-1α, is the only known ligand for CXCR4. CXCR4 mediates stem cell migration during embryonic development and in response to injury and inflammation. CXCR4 has been shown to play multiple roles in human diseases such as cell proliferative disorders, Alzheimer's disease, HIV, rheumatoid arthritis, and pulmonary fibrosis.
[0006] Integrin α v β3 (integrin αv β3) is a heterodimeric receptor located on the cell surface. It is rarely expressed in normal vascular endothelial and epithelial cells, but is highly expressed on the cell surface of various solid tumors such as lung cancer, osteosarcoma, neuroblastoma, breast cancer, prostate cancer, bladder cancer, glioblastoma and invasive melanoma. It is also highly expressed on the membrane of new blood vessels in all tumor tissues, suggesting that integrin α v β3 plays a key role in tumor growth, invasion and metastasis. Peptides containing the arginine-glycine-aspartic acid (RGD) sequence can bind to integrin α v β3-specific binding. Various radionuclide-labeled RGD peptides have been successfully used in imaging studies of various tumor-bearing animal models.
[0007] The effects of gastrin-releasing peptide (GRP) are primarily mediated through binding to its receptor, the GRP receptor (GRPR), a G protein-coupled receptor originally isolated from a small cell lung cancer cell line. Upregulation of the GRP / GRPR pathway has been reported in several cancers, including breast, prostate, uterine, ovarian, colon, pancreatic, gastric, lung (small cell and non-small cell lung cancer), head and neck squamous cell carcinoma, and various brain and neuroma tumors.
[0008] In the clinic, targeted compounds labeled with radionuclides have made significant progress in precision tumor imaging. Single-target radioligands require that tumor tissue specifically and highly express a specific receptor, while normal tissue expresses no or low levels of this receptor. During tumor growth, receptors on the surface of tumor cells exhibit heterogeneity and inhomogeneity. Even within patients with the same tumor, tumor tissue may express varying receptor types and levels. Currently reported probes suffer from limitations such as low uptake values, leaving room for improvement in diagnostic sensitivity and therapeutic efficacy.
[0009] Summary of the Invention
[0010] In order to solve one of the above technical problems existing in the prior art, the present invention provides a multi-target compound and its preparation method and application. In addition to targeting FAP receptors, the compound can also simultaneously target CXCR4, α v β3 or GRPR receptor.
[0011] The present invention provides a compound having a structure represented by formula (I) or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof.
[0012] in,
[0013] R 1 、R 3 and R 4are each independently selected from a bond, -U 1 -G 1 -A 1 -LA 2 -G 2 -U 2 - or heteroalkylene, R 1 、R 3 and R 4 At least one of them is -U 1 -G 1 -A 1 -LA 2 -G 2 -U 2 -;or for R 3 and R 4 At least one of them is -U 1 -G 1 -A 1 -LA 2 -G 2 -U 2 -;
[0014] L is or a bond, n1, n2, n3 and n4 are each independently 0, 1, 2 or 3;
[0015] A 1 and A 2 are each independently selected from a bond, -C(=O)NH-, -NHC(=O)- or -C(=O)-;
[0016] G 1 and G 2 Each independently selected from a bond, a heteroalkylene or z1 and z2 are each independently selected from 0, 1, 2 or 3;
[0017] U 1 and U 2 are each independently selected from a bond, Each t1 is independently selected from 1, 2, 3 or 4;
[0018] U 1 , G 1 、A 1 , L, A 2 , G 2 and U 2 Not a key at the same time;
[0019] m1, m2, m3 and m4 are each independently selected from 0, 1, 2, 3, 4 or 5;
[0020] Q1 , Q 2 and Q 3 One of the two is a chelating group, another is a group targeting FAP receptor, and the other is a group targeting other receptors, wherein the other receptors are selected from CXCR4 receptor, α v β3 receptor or GRPR receptor.
[0021] In some embodiments, Q 1 is a chelating group. In some embodiments, Q 2 is a group targeting FAP receptor; Q 3 is a group targeting said other receptors, said other receptors being selected from CXCR4 receptor, α v β3 receptor or GRPR receptor. In some embodiments, Q 2 is a group targeting said other receptors, said other receptors being selected from CXCR4 receptor, α v β3 receptor or GRPR receptor; Q 3 It is a group that targets the FAP receptor.
[0022] In some embodiments, Q 2 is a chelating group. In some embodiments, Q 1 is a group targeting FAP receptor; Q 3 is a group targeting said other receptors, said other receptors being selected from CXCR4 receptor, α v β3 receptor or GRPR receptor. In some embodiments, Q 1 is a group targeting said other receptors, said other receptors being selected from CXCR4 receptor, α v β3 receptor or GRPR receptor; Q 3 It is a group that targets the FAP receptor.
[0023] In some embodiments, Q 3 is a chelating group. In some embodiments, Q 1 is a group targeting FAP receptor; Q 2 is a group targeting said other receptors, said other receptors being selected from CXCR4 receptor, α v β3 receptor or GRPR receptor. In some embodiments, Q 1 is a group targeting said other receptors, said other receptors being selected from CXCR4 receptor, α v β3 receptor or GRPR receptor; Q 2 It is a group that targets the FAP receptor.
[0024] In some embodiments, Q 1 , Q 2 and Q 3One of them is a chelating group, another is a group targeting the FAP receptor, and another is a group targeting the CXCR4 receptor. 1 is a group targeting FAP receptor, Q 2 is a group targeting CXCR4 receptor, Q 3 is a chelating group; or Q 2 is a group targeting FAP receptor, Q 1 is a group targeting CXCR4 receptor, Q 3 A chelating group.
[0025] In some embodiments, Q 1 , Q 2 and Q 3 One of them is a chelating group, another is a group targeting FAP receptor, and the other is a group targeting α v In some embodiments, Q 1 is a group targeting FAP receptor, Q 2 is a group targeting αvβ3 receptor, Q 3 is a chelating group; or Q 2 is a group targeting FAP receptor, Q 1 To target α v β3 receptor group, Q 3 A chelating group.
[0026] In some embodiments, Q 1 , Q 2 and Q 3 One of them is a chelating group, another is a group targeting the FAP receptor, and another is a group targeting the GRPR receptor. In some embodiments, Q 1 is a group targeting FAP receptor, Q 2 is a group targeting GRPR receptor, Q 3 is a chelating group; or Q 2 is a group targeting FAP receptor, Q 1 is a group targeting GRPR receptor, Q 3 A chelating group.
[0027] In some embodiments, Q 1 is a group targeting FAP receptor, Q 2 is a group targeting CXCR4 receptor, Q 3 A chelating group.
[0028] In some embodiments, Q 2 is a group targeting FAP receptor, Q 1 is a group targeting CXCR4 receptor, Q 3 A chelating group.
[0029] In some embodiments, Q 1 is a group targeting FAP receptor, Q 2 To target α v β3 receptor group, Q 3 A chelating group.
[0030] In some embodiments, Q 2 is a group targeting FAP receptor, Q 1 To target α v β3 receptor group, Q 3 A chelating group.
[0031] In some embodiments, Q 1 is a group targeting FAP receptor, Q 2 is a group targeting GRPR receptor, Q 3 A chelating group.
[0032] In some embodiments, Q 2 is a group targeting FAP receptor, Q 1 is a group targeting GRPR receptor, Q 3 A chelating group.
[0033] In some embodiments, R 3 include The thioether bond in the main chain gives the compound better tumor targeting performance.
[0034] In some embodiments, the heteroalkylene group is an alkylene group containing at least one sulfur atom. In some embodiments, the heteroalkylene group is -(CH2) q -S-(CH2) p -, p and q are each independently selected from 0, 1, 2, 3, 4 or 5, and p and q are not both 0. In some embodiments, p is 0 or 1; q is 1 or 2.
[0035] In some embodiments, the compound has a structure represented by formula (I'-A), or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof:
[0036] Each symbol has the same definition as in formula (I),
[0037] Preferably, Q 1 is a group targeting FAP receptor, Q 2 To target other receptors such as CXCR4 receptor, α v β3 receptor or GRPR receptor group, Q 3 is a chelating group; or Q 2 is a group targeting FAP receptor, Q 1To target other receptors such as CXCR4 receptor, α v β3 receptor or GRPR receptor group, Q 3 is a chelating group;
[0038] Preferably, R 1 and R 3 One of the following: 1 -G 1 -A 1 -LA 2 -G 2 -U 2 -, another selected from key, U 1 or G 1 ;
[0039] L is n1, n2, n3 and n4 are each independently 0, 1, 2 or 3;
[0040] A 1 and A 2 are each independently selected from a bond, -C(=O)NH-, -NHC(=O)- or -C(=O)-;
[0041] G 1 and G 2 are each independently selected from a bond, -(CH2) q -S-(CH2) p -,or z1 and z2 are each independently selected from 0, 1, 2 or 3; p and q are each independently selected from 0, 1, 2, 3, 4 or 5, and p and q are not 0 at the same time;
[0042] U 1 and U 2 are each independently selected from a bond, Each t1 is independently selected from 1, 2, 3 or 4;
[0043] m1, m2, m3 and m4 are each independently selected from 0, 1, 2, 3, 4 or 5.
[0044] In some embodiments, the compound has a structure as shown in Formula I'-B, or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof:
[0045] Each symbol has the same definition as in formula (I),
[0046] Preferably, Q 1 is a group targeting FAP receptor, Q 2 For the group targeting said other receptors such as GRPR receptor, Q 3is a chelating group; or Q 2 is a group targeting FAP receptor, Q 1 For the group targeting said other receptors such as GRPR receptor, Q 3 is a chelating group;
[0047] R 1 and R 3 One of the following: 1 -G 1 -A 1 -LA 2 -G 2 -U 2 -, another selected from a bond, -(CH2) q -S-(CH2) p -、U 1 or G 1 ; p and q are each independently selected from 0, 1, 2, 3, 4 or 5, and p and q are not 0 at the same time;
[0048] L is n1, n2, n3 and n4 are each independently 0, 1, 2 or 3;
[0049] A 1 and A 2 are each independently selected from a bond, -C(=O)NH-, -NHC(=O)- or -C(=O)-;
[0050] G 1 and G 2 Each independently selected from a bond or z1 and z2 are each independently selected from 0, 1, 2 or 3;
[0051] U 1 and U 2 are each independently selected from a bond, Each t1 is independently selected from 1, 2, 3 or 4;
[0052] m1, m2 and m3 are each independently selected from 0, 1, 2, 3, 4 or 5.
[0053] In some embodiments, the compound has the structure shown in Formula I'-C, or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof;
[0054] The definitions of each symbol are the same as those in Formula I. Preferably, Q 1 is a group targeting FAP receptor, Q 3 To target other receptors such as α v β3 receptor group, Q 2is a chelating group; or Q 3 is a group targeting FAP receptor, Q 1 To target other receptors such as α v β3 receptor group, Q 2 is a chelating group;
[0055] Preferably, R 1 and R 4 One of the following: 1 -G 1 -A 1 -LA 2 -G 2 -U 2 -, another selected from a bond, -(CH2) q -S-(CH2) p -、U 1 or G 1 ; p and q are each independently selected from 0, 1, 2, 3, 4 or 5, and p and q are not 0 at the same time;
[0056] or, for R 4 -U 1 -G 1 -A 1 -LA 2 -G 2 -U 2 -;
[0057] L is n1, n2, n3 and n4 are each independently 0, 1, 2 or 3;
[0058] A 1 and A 2 are each independently selected from a bond, -C(=O)NH-, -NHC(=O)- or -C(=O)-;
[0059] G 1 and G 2 Each independently selected from a bond or z1 and z2 are each independently selected from 0, 1, 2 or 3;
[0060] U 1 and U 2 are each independently selected from a bond, Each t1 is independently selected from 1, 2, 3 or 4;
[0061] m1, m2 and m3 are each independently selected from 0, 1, 2, 3, 4 or 5.
[0062] In some embodiments, the compound has the structure shown in I-2 or its stereoisomers, tautomers, and pharmaceutically acceptable salts:
[0063] In formula I-2, Q 1 , Q 2 , Q 3 The definition is the same as that in formula (I); preferably, Q 1 is a group targeting FAP receptor; Q 2 is a group that targets other receptors such as CXCR4 receptor; Q 3 is a chelating group; or Q 1 is a group that targets other receptors such as CXCR4 receptor; Q 2 is a group targeting FAP receptor; Q 3 A chelating group.
[0064] In some embodiments, the compound has a structure represented by Formula I-1, I-3, or I-4, or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof:
[0065] Among them, Q 1 , Q 2 , Q 3 The definition is the same as that in formula (I); preferably, Q 2 is a group targeting FAP receptor; Q 1 is a group that targets other receptors such as CXCR4 receptor; Q 3 is a chelating group; or Q 1 is a group targeting FAP receptor; Q 2 is a group that targets other receptors such as CXCR4 receptor; Q 3 A chelating group.
[0066] In some embodiments, the compound has a structure represented by Formula I-5, I-6, I-7 or I-8, or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof:
[0067] In formula I-5, Q 1 , Q 2 , Q 3 The definition is the same as that in formula (I); preferably, Q 1 is a group that targets other receptors such as GRPR receptor; Q 2 is a group targeting FAP receptor; Q 3 is a chelating group; or Q 2 is a group that targets other receptors such as GRPR receptor; Q 1 is a group targeting FAP receptor; Q3 is a chelating group;
[0068] In formula I-6, Q 1 , Q 2 , Q 3 The definition is the same as that in formula (I); preferably, Q 1 is a group targeting FAP receptor; Q 2 is a group that targets other receptors such as GRPR receptor; Q 3 is a chelating group; or Q 2 is a group targeting FAP receptor; Q 1 is a group that targets other receptors such as GRPR receptor; Q 3 is a chelating group;
[0069] In formulas I-7 and I-8, Q 1 , Q 2 , Q 3 The definition is the same as that in formula (I); preferably, Q 1 is a group targeting FAP receptor; Q 2 is a chelating group; Q 3 To target other receptors such as α v β3 receptor group; or Q 3 is a group targeting FAP receptor; Q 2 is a chelating group; Q 1 To target other receptors such as α v β3 receptor group.
[0070] In some embodiments, the compound has a structure represented by Formula II-A, II-B, II-C-1, II-C-2, or II-D, or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof:
[0071] In II-A, the definitions of the symbols are the same as those in Formula I. Preferably, Q 1 is a group targeting the FAP receptor;
[0072] In II-B, the definitions of the symbols are the same as those in Formula I. Preferably, Q 2 is a group targeting the FAP receptor;
[0073] In II-C1 and II-C2, the definitions of the symbols are the same as those in Formula I. Preferably, Q 1 is a group targeting FAP receptor; Q 2 is a chelating group;
[0074] In II-D, the definitions of the symbols are the same as those in Formula I. Preferably, Q 1 It is a group that targets the FAP receptor.
[0075] In some embodiments, the compound has a structure represented by Formula III-1 or III-2 or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof:
[0076] Wherein, the definitions of the symbols are the same as those in Formula I; preferably, Q 2 It is a group that targets the FAP receptor.
[0077] In some embodiments, the compound has the structure shown in Formula V:
[0078] Among them, each U 1 are each independently selected from a bond, Each t1 is independently selected from 1, 2, 3 or 4;
[0079] m1, m2, m3 and m4 are each independently selected from 0, 1, 2, 3, 4 or 5;
[0080] y is an integer selected from 3 to 10;
[0081] Q 1 is a group targeting the FAP receptor,
[0082] Q 2 is a chelating group,
[0083] Q 3 To target α v β3 receptor group.
[0084] Preferably, Q 1 Selected from:
[0085] In some embodiments, the group targeting the FAP receptor is the structure shown in II-1:
[0086] M 1 、M 2 、M 3 、M 4 、M 5 、M 6 、M 7 independently selected from a bond, -O-, -CH2-, -NR 8 -, -C(=O)-, -C(=S)-, -C(=NH)R 8 -、-CHR8 -and-C(R 8 )2-, provided that the two Os are not directly adjacent to each other; M 1 、M 2 、M 3 、M 4 、M 5 、M 6 、M 7 At most 4 of them are keys at the same time;
[0087] R 6 and R 7 Independently selected from -H, -OH, halogen, C 1-6 Alkyl, -OC 1-6 Alkyl, -SC 1-6 alkyl;
[0088] R 5 Selected from -H, -CN, -B(OH)2, -C(=O)-alkyl, -C(=O)-aryl-, -C=CC(=O)-aryl, -C=CS(=O)2-aryl, -C(=O)OH, -S(=O)2OH, -S(=O)2NH2, -P(=O)(OH)2 and 5-tetrazolyl;
[0089] R 8 Selected from -H, C 1-6 Alkyl, -OC 1-6 Alkyl, -SC 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Heteroalkenyl, C 5-6 Cycloalkenyl, C 4-6 Cycloheteroalkenyl, C 2-6 Alkynyl, C 6-10 Aryl and C 6-10 Aryl C 1-6 Alkyl, the C 1-6 The alkyl group is optionally substituted with 1 to 3 substituents selected from -OH, oxygen, and halogen;
[0090] Ring W is selected from naphthyl and 5-10 membered nitrogen heteroaryl.
[0091] In some embodiments, -M 1 -M 2 -M 3 -M 4 -M 5 -M 6 -M 7 - is -C(=O)-CH2-NR 8 -C(=O)-.
[0092] In some embodiments, R 6 and R7 Independently selected from -H or F.
[0093] In some embodiments, Ring W is quinolinyl; in still other embodiments, Ring W is 4-quinolinyl.
[0094] In some embodiments, for
[0095] In some embodiments, the group targeting the FAP receptor is the structure shown in II-2:
[0096] R 9 is an alkyl acyl group;
[0097] R 10 、R 11 are each independently selected from H or CH3;
[0098] p1 is selected from 0 or 1; p2 is selected from 1 or 2;
[0099] Xaa 2 、Xaa 3 、Xaa 4 、Xaa 5 and Xaa 6 Each independently selected from conventional amino acid residues and unconventional amino acid residues;
[0100] Preferably,
[0101] Xaa 2 for
[0102] R 12 、R 13 、R 14 Each independently selected from C 1-2 Alkyl, carboxyl and H, wherein the C 1-2 The alkyl group is optionally substituted by one or two groups selected from OH, NH2, halogen, C 5-7 Substitution of cycloalkyl groups; The 3- and 4-positions of are optionally substituted by one or two substituents selected from methyl, OH, NH2 and F;
[0103] q1 is selected from 0, 1 or 2;
[0104] q2 is selected from 1, 2 or 3;
[0105] q3 is selected from 1 or 2;
[0106] Xaa 3 yes
[0107] X1 Selected from CH2, CF2, CHR 16 , S, O and NH;
[0108] R 15 is H, methyl, OH, NH2 or F,
[0109] R 16 is methyl, OH, NH2 or F;
[0110] Xaa 4 yes
[0111] R 17 is methyl or H;
[0112] R 18 Selected from H, -OH, -C(=O)OH, -(C=O)NH2, X 2 and -NH-C(=O)-X 2 , where X 4 Selected from C 1-6 Alkyl, phenyl and C 5-6 heteroaryl, and X 2 optionally substituted with one or two substituents selected from methyl, C(=O)NH2, halogen, NH2 and OH;
[0113] q4 is selected from 1, 2 or 3; wherein optionally, one or two hydrogens of said 1, 2 or 3 CH2 groups are each and independently substituted by methyl, ethyl, phenyl or C 5-6 Heteroaryl substitution,
[0114] Xaa 5 yes
[0115] R 19 Selected from OH and NH2;
[0116] q5 is selected from 1, 2 or 3;
[0117] Xaa 6 An amino acid residue selected from aromatic L-α-amino acids and heteroaromatic L-α-amino acids.
[0118] In some embodiments, the group targeting the FAP receptor is:
[0119] In some embodiments, the group targeting the GRPR receptor is a structure shown in Formula III:
[0120] -Xaa 7 —Xaa 8 —Xaa 9 —Xaa 10—Xaa 11 —Xaa 12 —Xaa 13 —C(═O)-Z(III);
[0121] Xaa 7 、Xaa 8 、Xaa 9 、Xaa 10 、Xaa 11 、Xaa 12 、Xaa 13 Each independently selected from conventional amino acid residues and unconventional amino acid residues;
[0122] Preferably,
[0123] Xaa 7 Absent or selected from the group consisting of amino acid residues Asn, Thr, Phe, Thi, Cpa, naphthylalanine, β-naphthylalanine, Tpi, Tyr, oI-Tyr, Trp, 5F-Phe;
[0124] Xaa 8 Selected from amino acid residues Gin, Asn, His;
[0125] Xaa 9 Selected from amino acid residues Trp and Tpi;
[0126] Xaa 10 Selected from the group consisting of amino acid residues Ala, Ser, Val;
[0127] Xaa 11 Selected from amino acid residues Val, Ser, Thr;
[0128] Xaa 12 Selected from amino acid residues Gly, Sar, D-Ala, β-Ala
[0129] Xaa 13 Selected from the group consisting of amino acid residues His, (3-Me)His;
[0130] Z is selected from -NHOH, -NHNH2, -NH-alkyl, -N(alkyl)2, -O-alkyl, -NH-CHR 23 R 24 or -O-CHR 23 R 24 ; R 23 and R 24 are the same or different, each independently selected from H, alkyl, alkyl ether, aryl, aryl ether, arylalkyl, halogen, hydroxyl, and hydroxyalkyl-substituted aryl;
[0131] The group targeting the GRPR receptor is through Xaa7 connected to the rest of the molecule.
[0132] In some embodiments, the group targeting the FAP receptor is: In some embodiments, the group targeting the FAP receptor is
[0133] In some embodiments, the group targeting the CXCR4 receptor is selected from:
[0134] In some embodiments, the group targeting the GRPR receptor is:
[0135] In some embodiments, the targeting α v The groups of β3 receptors are:
[0136] In some embodiments, the chelating group is selected from 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA), 1,4,7,10-tetraazacyclododecane, 1-(pentanedioic acid)-4,7,10-triacetic acid (DOTAGA), 1,4,7-triazacyclononane triacetic acid (NOTA), 1,4,7-triazacyclononane-N-pentanedioic acid-N',N"-diacetic acid (NODAGA), 1,4,7-triazacyclononane-1,4-diacetic acid-methylphenylacetic acid (NODA-MPAA), bis(2-hydroxybenzyl)ethylenediaminediacetic acid (HBED), 4,11-bis-(carboxymethylmethyl)-1,4,8,11-tetraazabicyclo[6.6.2]-hexadecane (CB-TE2A), DFO or a hexadentate tris(3,4-hydroxypyridone) (THP)-derived group.
[0137] In some embodiments, the chelating group is one of the following groups:
[0138] In some embodiments, the chelating group is
[0139] In some embodiments, the chelating group is
[0140] In some embodiments, R 1 is the key.
[0141] In some embodiments, R 1 is a heteroalkylene group, for example, the heteroalkylene group is -(CH2) q -S-(CH2) p-, preferably q is selected from 0, 1 or 2; p is selected from 0, 1 or 2.
[0142] In some embodiments, R 1 -U 1 -G 1 -A 1 -LA 2 -G 2 -U 2 -, where: L is A 2 -C(=O)NH-, A 1 、U 1 、U 2 , G 1 , G 2 are all bonds. It is easy for those skilled in the art to understand that when A 1 、U 1 、U 2 , G 1 , G 2 When both are keys, R 1 For LA 2 .
[0143] In some embodiments, R 3 is the key.
[0144] In some embodiments, R 3 -U 1 -G 1 -A 1 -LA 2 -G 2 -U 2 -, where: U 2 for t1=3;A 1 、A 2 , L, U 1 , G 1 , G 2 are all bonds. It is easy for those skilled in the art to understand that when A 1 、A 2 , L, U 1 , G 1 , G 2 When both are keys, R 3 For U 2 .
[0145] In some embodiments, R 3 -U 1 -G 1 -A 1 -LA 2 -G 2 -U 2 -, where: L is A 2 -NHC(=O)-, G 2 for U 2 for A 1 、U 1 and G 1 All are keys.
[0146] In some embodiments, R 4 -U 1 -G 1 -A 1 -LA 2 -G 2 -U 2 -, where: G 1 for A 1 is -C(=O)NH-;
[0147] L is U 2 for U 1 、A 2 and G 2 All are keys.
[0148] In some embodiments, R 4 is the key.
[0149] In some embodiments, t1=3.
[0150] In some embodiments, m1=2.
[0151] In some embodiments, m2=4.
[0152] In some embodiments, m3=1.
[0153] In some embodiments, m4=2.
[0154] In some embodiments, n1=2, and / or n2=1, and / or n3=1, and / or n4=1.
[0155] In some embodiments, n1=2, and / or n2=0, and / or n3=2, and / or n4=2.
[0156] In some embodiments, U 1 For keys and / or G 1 For keys and / or A 1 is the key.
[0157] In some embodiments, R 1 -U 1 -G 1-A 1 -LA 2 -G 2 -U 2 -, where: L is n1=2, n2=1, n3=1, n4=1, A 2 -C(=O)NH-; A 1 、U 1 、U 2 , G 1 , G 2 All are keys;
[0158] R 3 -U 1 -G 1 -A 1 -LA 2 -G 2 -U 2 -, where: U 2 for t1=3;
[0159] A 1 、A 2 , L, U 1 , G 1 , G 2 All are bonds; R 4 is a key; m1=2, m2=4, m3=1, Q 1 It is a group targeting CXR4 receptor; Q 2 is a group targeting FAP receptor; Q 3 It is a chelating group.
[0160] In some embodiments, R 1 is a key; R 3 -U 1 -G 1 -A 1 -LA 2 -G 2 -U 2 -, where: L is n1=2, n2=1, n3=1, n4=1; A 2 -NHC(=O)-, G 2 for U 2 for U 1 , G 1 and A 1 All are bonds; R 4 is a key; m2=4, m3=1, m4=2; Q 1 is a group targeting FAP receptor; Q 2It is a group targeting CXR4 receptor; Q 3 It is a chelating group.
[0161] In some embodiments, R 1 -U 1 -G 1 -A 1 -LA 2 -G 2 -U 2 -; where L is n1=2, n2=1, n3=1, n4=1, A 2 -C(=O)NH-; U 1 , G 1 、A 2 , G 2 、U 2 All are keys;
[0162] R 3 -U 1 -G 1 -A 1 -LA 2 -G 2 -U 2 -, where: U 1 for t1=3,G 1 、A 1 , L, A 2 , G 2 、U 2 All are keys;
[0163] R 4 is a key; m1 = 2; m2 = 4, m3 = 1, Q 1 is a group targeting GRPR receptor; Q 2 is a group targeting FAP receptor; Q 3 It is a chelating group.
[0164] In some embodiments, R 1 is the key;
[0165] R 3 -U 1 -G 1 -A 1 -LA 2 -G 2 -U 2 -, where: L is n1=2, n2=1, n3=1, n4=1; A 1 -C(=O)NH-, U 1 , G 1 、A 2 , G2 、U 2 All are keys;
[0166] R 4 is a key; m2=4, m3=1, m4=2, Q 1 is a group targeting FAP receptor; Q 2 is a group targeting GRPR receptor; Q 3 It is a chelating group.
[0167] In some embodiments, R 1 is the key;
[0168] R 3 -U 1 -G 1 -A 1 -LA 2 -G 2 -U 2 -, where: L is
[0169] n1=2, n2=1, n3=1, n4=1; A 1 -C(=O)NH-; U 2 for t1=3,
[0170] U 1 , G 1 , A 2 , G 2 All are bonds; R 4 is a key; m4=1, m2=4, m3=1,m1=2,
[0171] Q 1 It is a group targeting CXCR4 receptor; Q 2 is a group targeting FAP receptor; Q 3 It is a chelating group.
[0172] In some embodiments, R 1 is the key;
[0173] R 3 -U 1 -G 1 -A 1 -LA 2 -G 2 -U 2 -, where: G 1 for A 1 is -C(=O)NH-;
[0174] L is n1=2, n2=1, n3=1, n4=1;
[0175] U 2 for U 1 、A 2 and G 2 All are keys,
[0176] R 4 is a key; m4=1, m2=4, m3=1,
[0177] Q 1 It is a group that targets the FAP receptor;
[0178] Q 2 It is a group that targets the CXCR4 receptor;
[0179] Q 3 It is a chelating group.
[0180] In some embodiments, for R 3 is the key;
[0181] R 4 -U 1 -G 1 -A 1 -LA 2 -G 2 -U 2 -, where: G 1 for A 1 is -C(=O)NH-;
[0182] L is n1=2, n2=0, n3=2, n4=2;
[0183] U 2 for U 1 , A 2 , G 2 is the key;
[0184] m1=2,m2=4;
[0185] Q 1 It is a group that targets the FAP receptor
[0186] Q 2 is a chelating group; for example, a chelating group is
[0187] Q 3 Targeted α v β3 receptor group.
[0188] In this embodiment, the above structure is used to make the targeting group Q 3 and chelating group Q 2 The longer linker length between them has better dual targeting.
[0189] In some embodiments, R 1 is a heteroalkylene group such as -(CH2) q -S-(CH2) p -, preferably q is selected from 0, 1 or 2; p is selected from 0, 1 or 2;
[0190] R 3 is the key;
[0191] R 4 -U 1 -G 1 -A 1 -LA 2 -G 2 -U 2 -, where: G 1 for A 1 is -C(=O)NH-;
[0192] L is n1=2, n2=0, n3=2, n4=2;
[0193] U 2 for U 1 , A 2 , G 2 is the key;
[0194] m1=2,m2=4;Q 1 is a group targeting FAP receptor; Q 2 is a chelating group; Q 3 Targeted α v β3 receptor group.
[0195] In some embodiments, the compound is selected from the following structures or stereoisomers, tautomers, and pharmaceutically acceptable salts thereof:
[0196] In another aspect, the present invention provides a method for preparing compound SDYD01, comprising:
[0197] 1) Compound 1-1 reacts with compound 1-2 to produce compound 1-3;
[0198] 2) Compound 1-3 reacts with compound 1-4 to generate compound SDYD01;
[0199] In another aspect, the present invention provides a method for preparing compound SDYD02, comprising:
[0200] 1) Compound 2-1 reacts with compound 2-2 to produce compound 2-3;
[0201] 2) Compound 2-3 reacts with compound 2-4 to generate compound SDYD02;
[0202] In another aspect, the present invention provides a method for preparing compound SDYD05, comprising:
[0203] 1) Compound 5-1 reacts with compound 5-2 to produce compound 5-3;
[0204] 2) Compound 5-3 reacts with compound 5-4 to generate compound 5-5;
[0205] 3) Compound 5-5 reacts with compound 5-6 to produce compound 5-7;
[0206] 4) Compound 5-7 reacts with compound 5-8 to generate compound SDYD05;
[0207] In another aspect, the present invention provides a method for preparing compound SDYD06, comprising:
[0208] 1) Compound 6-1 reacts with compound 6-2 to produce compound 6-3;
[0209] 2) Compound 6-3 reacts with compound 6-4 to produce compound 6-5;
[0210] 3) Compound 6-5 reacts with compound 6-6 to produce compound 6-7;
[0211] 4) Compound 6-7 reacts with compound 6-8 to generate compound SDYD06;
[0212] In another aspect, the present invention provides a method for preparing compound SDYD03, comprising:
[0213] 1) Compound 3-1 reacts with compound 3-2 to form compound 3-3;
[0214] 2) Compound 3-3 reacts with compound 3-4 to generate compound SDYD03;
[0215] In another aspect, the present invention provides a method for preparing compound SDYD04, comprising:
[0216] 1) Compound 4-1 reacts with compound 4-2 to produce compound 4-3;
[0217] 2) Compound 4-3 reacts with compound 4-4 to generate compound SDYD04;
[0218] In another aspect, the present invention provides a method for preparing compound SDYD07, comprising:
[0219] 1) Compound 7-1 reacts with compound 7-2 to produce compound 7-3;
[0220] 2) Compound 7-3 reacts with compound 7-4 to produce compound 7-5;
[0221] 3) Compound 7-5 reacts with compound 7-6 to generate compound 7-7;
[0222] 4) Compound 7-8 reacts with compound 7-9 to produce compound 7-10;
[0223] 5) Compound 7-10 reacts with compound 7-11 to produce compound 7-12;
[0224] 6) Compound 7-12 reacts with compound 7-7 to generate compound SDYD07;
[0225] In another aspect, the present invention provides a method for preparing compound SDYD08, comprising:
[0226] 1) Compound 8-1 reacts with compound 8-2 to produce compound 8-3;
[0227] 2) Compound 8-3 reacts with compound 8-4 to produce compound 8-5;
[0228] 3) Compound 8-5 reacts with compound 8-6 to generate compound 8-7;
[0229] 4) Compound 8-7 reacts with compound 8-8 to generate compound SDYD08;
[0230] In another aspect, the present invention provides a radionuclide-labeled compound, which is obtained by labeling the compound of the present invention with a radionuclide.
[0231] In some embodiments, the radioactive moiety is a fluorescent isotope, a radioisotope, a radiopharmaceutical, or a combination thereof.
[0232] In some embodiments, the radionuclide is selected from the group consisting of alpha-emitting isotopes, beta-emitting isotopes, gamma-emitting isotopes, Auger-emitting isotopes, X-ray-emitting isotopes, and fluorescence-emitting isotopes; preferably, the radionuclide is selected from the group consisting of 18 F. 51 Cr, 67 Ga, 68 Ga, 111 In, 99m Tc, 186 Re、 188 Re、 139 La, 140 La, 175 Yb, 153 Sm, 166 Ho, 88 Y. 90 Y. 149 Pm, 165 Dy, 169 Second, 177 Lu, 47 Sc, 142 Pr, 159 Gd, 212 Bi, 213 Bi, 72 As、 72 Se, 97 Such as 109 Pd, 105 Rh, 101m Rh, 119 Sb, 128 Ba, 123 I. 124 I. 131 I. 197 Hg, 211 At 151 Eu, 153 Eu, 169 Eu,201 Tl, 203 Pb, 212 Pb, 64 Cu, 67 Cu, 188 Re、 186 Re、 198 Au, 225 Ac, 227 Th and 199 Ag.
[0233] In some embodiments, the radionuclide is selected from 18 F. 51 Cr, 67 Ga, 68 Ga, 111 In, 99m Tc, 186 Re、 188 Re、 139 La, 140 La, 175 Yb, 153 Sm, 166 Ho, 88 Y. 90 Y. 149 Pm, 165 Dy, 169 Second, 177 Lu, 47 Sc, 142 Pr, 159 Gd, 212 Bi, 213 Bi, 72 As、 72 Se, 97 Such as 109 Pd, 105 Rh, 101m Rh, 119 Sb, 128 Ba, 123 I. 124 I. 131 I. 197 Hg, 211 At 151 Eu, 153 Eu, 169 Eu, 201 Tl, 203 Pb, 212 Pb, 64 Cu, 67 Cu, 188 Re、 186 Re、 198 Au, 225 Ac,227 Th and 199 Ag.
[0234] In some embodiments, the radionuclide is selected from 68 Ga and 177 Lu.
[0235] In some embodiments, the radionuclide-labeled compound is selected from:
[0236] In addition, the present invention also provides a pharmaceutical composition, which comprises or consists of at least one compound described in the present invention and optionally a pharmaceutically acceptable carrier and / or excipient.
[0237] In addition, the present invention also provides the compound or pharmaceutical composition of the present invention for use in diagnosing or treating FAP, CXCR4, GRPR, α v The invention relates to a method or use for treating a disease characterized by abnormal expression of one or both of β3.
[0238] In some embodiments, the disease is characterized by aberrant expression of one or both of FAP and CXCR4;
[0239] In some embodiments, the disease is characterized by aberrant expression of one or both of FAP and GRPR;
[0240] In some embodiments, the disease is characterized by FAP and α v The abnormal expression of one or both of β3 is characteristic;
[0241] In some embodiments, the disease is selected from cancer, chronic inflammation, atherosclerosis, fibrosis, tissue remodeling and scar disease, preferably, wherein the cancer is selected from breast cancer, pancreatic cancer, small intestine cancer, colon cancer, rectal cancer, lung cancer, head and neck cancer, ovarian cancer, hepatocellular carcinoma, esophageal cancer, hypopharyngeal cancer, nasopharyngeal cancer, laryngeal cancer, myeloma cells, bladder cancer, bile duct cell carcinoma, clear cell renal carcinoma, neuroendocrine tumors, carcinogenic osteomalacia, sarcoma, CUP (cancer of unknown primary), thymic cancer, glioma, glioma, astrocytoma, cervical cancer and prostate cancer.
[0242] In addition, the present invention also provides a kit, which contains or consists of the compound or pharmaceutical composition of the present invention.
[0243] The compound structure provided by the present invention can synergistically target FAP target and CXCR4 target, FAP target and GRPR target or FAP target and α v β3 target, can increase the number of effective receptors in tumors and utilization efficiency, with better specific targeting, higher tumor uptake efficiency and better tumor retention ability, and can be cleared faster by non-tumor tissues. The radiolabeled compounds further provided based on this structure are expected to be used in the diagnosis or treatment of FAP, CXCR4, GRPR or α v Diseases characterized by abnormal expression of β3. BRIEF DESCRIPTION OF THE DRAWINGS
[0244] FIG1 shows a high performance liquid chromatogram of SDYD01.
[0245] FIG2 shows the mass spectrum of SDYD01.
[0246] Figure 3 shows the radiochemical purity analysis of radiolabeled SDYD01, (a) 68 Radiochemical purity of Ga-SDYD01; (b) 177 Lu-SDYD01 is radiochemically pure.
[0247] Figure 4 shows 68 Stability study of Ga-SDYD01 in buffer, (a) 0.5 hour; (b) 1 hour; (c) 2 hours.
[0248] Figure 5 shows 177 Stability study of Lu-SDYD01 in buffer, (a) 24 hours; (b) 48 hours; (c) 120 hours.
[0249] Figure 6 shows 68 Competition experiment of Ga-SDYD01 with radioligand in histidine and cysteine solutions, (a) 2 hours in 10 mM cysteine solution; (b) 2 hours in 10 mM histidine solution.
[0250] FIG7 shows a high performance liquid chromatogram of SDYD02.
[0251] FIG8 shows the mass spectrum of SDYD02.
[0252] Figure 9 shows the radiochemical purity analysis of the radiolabeled compound SDYD02, (a) 68 Radiochemical purity of Ga-SDYD02; (b) 177 Lu-SDYD02 is radiochemically pure.
[0253] Figure 10 shows 68Stability study of Ga-SDYD02 in buffer, (a) 0.5 hour; (b) 1 hour; (c) 2 hours.
[0254] Figure 11 shows 177 Stability study of Lu-SDYD02 in buffer, (a) 24 hours; (b) 48 hours; (c) 120 hours.
[0255] Figure 12 shows 68 Competition experiment of Ga-SDYD02 with radioligand in histidine and cysteine solutions, (a) 2 hours in 10 mM cysteine solution (b) 2 hours in 10 mM histidine solution.
[0256] FIG13 shows a high performance liquid chromatogram of SDYD05.
[0257] FIG14 shows the mass spectrum of SDYD05.
[0258] Figure 15 shows the radiochemical purity analysis of radiolabeled SDYD05, (a) 68 Radiochemical purity of Ga-SDYD05; (b) 177 Lu-SDYD05 is radiochemically pure.
[0259] Figure 16 shows 68 Stability study of Ga-SDYD05 in buffer, (a) 0.5 hour; (b) 1 hour; (c) 2 hours
[0260] Figure 17 shows 177 Stability study of Lu-SDYD05 in buffer, (a) 24 hours; (b) 48 hours; (c) 120 hours.
[0261] FIG18 shows 68 Competition experiment of Ga-SDYD05 with radioligand in histidine and cysteine solutions, (a) 2 hours in 10 mM cysteine solution; (b) 2 hours in 10 mM histidine solution.
[0262] FIG19 shows a high performance liquid chromatogram of SDYD06.
[0263] FIG20 shows the mass spectrum of SDYD06.
[0264] Figure 21 shows the radiochemical purity analysis of radiolabeled SDYD06, (a) 68 Radiochemical purity of Ga-SDYD06; (b) 177 Lu-SDYD06 is radiochemically pure.
[0265] Figure 22 shows 68Stability study of Ga-SDYD06 in buffer, (a) 0.5 hour; (b) 1 hour; (c) 2 hours.
[0266] Figure 23 shows 68 Competition experiment of Ga-SDYD06 with radioligand in histidine and cysteine solutions, (a) 2 hours in 10 mM cysteine solution; (b) 2 hours in 10 mM histidine solution.
[0267] FIG24 shows a high performance liquid chromatogram of SDYD03.
[0268] FIG25 shows the mass spectrum of SDYD03.
[0269] Figure 26 shows the radiochemical purity analysis of the radiolabeled compound SDYD03, (a) 68 Radiochemical purity of Ga-SDYD02; (b) 177 Lu-SDYD03 is radiochemically pure.
[0270] FIG27 shows 68 Stability study of Ga-SDYD03 in buffer, (a) 0.5 hour; (b) 1 hour; (c) 2 hours.
[0271] Figure 28 shows 177 Stability study of Lu-SDYD03 in buffer, (a) 24 hours; (b) 48 hours; (c) 120 hours.
[0272] FIG29 shows a high performance liquid chromatogram of SDYD04.
[0273] FIG30 shows the mass spectrum of SDYD04.
[0274] Figure 31 shows the radiochemical purity analysis of radiolabeled compound SDYD04, (a) 68 Radiochemical purity of Ga-SDYD02; (b) 177 Lu-SDYD04 is radiochemically pure.
[0275] Figure 32 shows 68 Stability study of Ga-SDYD04 in buffer, (a) 0.5 hour; (b) 1 hour; (c) 2 hours.
[0276] FIG33 shows 177 Stability study of Lu-SDYD04 in buffer, (a) 24 hours; (b) 48 hours; (c) 120 hours.
[0277] FIG34 shows a high performance liquid chromatogram of SDYD07.
[0278] FIG35 shows the mass spectrum of SDYD07.
[0279] Figure 36 shows the radiochemical purity analysis of radiolabeled SDYD07, (a) 68 Radiochemical purity of Ga-SDYD07; (b) 177 Lu-SDYD07 is radiochemically pure.
[0280] FIG37 shows 68 Stability study of Ga-SDYD07 in buffer, (a) 0.5 hour; (b) 1 hour; (c) 2 hours.
[0281] FIG38 shows 177 Stability study of Lu-SDYD07 in buffer, (a) 24 hours; (b) 48 hours; (c) 120 hours.
[0282] FIG39 shows a high performance liquid chromatogram of SDYD08.
[0283] FIG40 shows the mass spectrum of SDYD08.
[0284] Figure 41 shows the radiochemical purity analysis of radiolabeled SDYD08, (a) 68 Radiochemical purity of Ga-SDYD08; (b) 177 Lu-SDYD08 is radiochemically pure.
[0285] FIG42 shows 68 Stability study of Ga-SDYD08 in buffer, (a) 0.5 hour; (b) 1 hour; (c) 2 hours.
[0286] FIG43 shows 177 Stability study of Lu-SDYD08 in buffer, (a) 24 hours; (b) 48 hours; (c) 120 hours.
[0287] FIG44 shows 68 Results of the Ga-SDYD01 cellular uptake experiment: (a) is the radioactivity count of cellular uptake, and (b) is the inhibition rate at each time point.
[0288] Figure 45 shows 68 Results of the Ga-SDYD03 cell uptake experiment: (a) is the radioactivity count of cell uptake, and (b) is the inhibition rate at each time point.
[0289] FIG46 shows 68 Results of the Ga-SDYD04 cell uptake experiment: (a) is the radioactivity count of cell uptake, and (b) is the inhibition rate at each time point.
[0290] FIG47 shows 68 Results of the Ga-SDYD05 cell uptake experiment: (a) is the radioactivity count of cell uptake, and (b) is the inhibition rate at each time point.
[0291] FIG48 shows 68 Results of the Ga-SDYD06 cell uptake experiment: (a) is the radioactivity count of cell uptake, and (b) is the inhibition rate at each time point.
[0292] FIG49 shows 68 Results of the Ga-SDYD07 cell uptake experiment: (a) is the radioactivity count of cell uptake, and (b) is the inhibition rate at each time point.
[0293] FIG50 shows 68 Results of the Ga-SDYD08 cell uptake experiment: (a) is the radioactivity count of cell uptake, and (b) is the inhibition rate at each time point.
[0294] FIG51 shows 68 Animal experimental results of Ga-SDYD01, (a) PET / CT imaging of tumor-bearing mice, (b) biodistribution data in tumor-bearing mice.
[0295] FIG52 shows 68 Animal experimental results of Ga-SDYD02, (a) PET / CT imaging of tumor-bearing mice, (b) biodistribution data in tumor-bearing mice.
[0296] FIG53 shows 68 Animal experimental results of Ga-SDYD03, (a) PET / CT imaging of tumor-bearing mice, (b) biodistribution data in tumor-bearing mice.
[0297] Figure 54 shows 68 Animal experimental results of Ga-SDYD04, (a) PET / CT imaging of tumor-bearing mice, (b) biodistribution data in tumor-bearing mice.
[0298] Figure 55 shows 68 Animal experimental results of Ga-SDYD05, (a) PET / CT imaging of tumor-bearing mice, (b) biodistribution data in tumor-bearing mice.
[0299] FIG. 56 shows 68 Animal experimental results of Ga-SDYD06, (a) PET / CT imaging of tumor-bearing mice, (b) biodistribution data in tumor-bearing mice.
[0300] FIG. 57 shows 68Animal experimental results of Ga-SDYD07: (a) PET / CT imaging of tumor-bearing mice, (b) biodistribution data in tumor-bearing mice; (c) relative ratio of radioactive uptake in tumor / normal tissues of tumor-bearing mice.
[0301] FIG. 58 shows 68 Animal experimental results of Ga-SDYD08: (a) PET / CT imaging of tumor-bearing mice, (b) biodistribution data in tumor-bearing mice; (c) relative ratio of radioactive uptake in tumor / normal tissues of tumor-bearing mice.
[0302] FIG59 shows 68 Animal experimental results of Ga-FAPI04, (a) PET / CT imaging of tumor-bearing mice, (b) biodistribution data in tumor-bearing mice.
[0303] FIG. 60 shows 68 Animal experimental results of Ga-FAP2286, (a) PET / CT imaging of tumor-bearing mice, (b) biodistribution data in tumor-bearing mice.
[0304] Figure 61 shows 68 Biodistribution data of Ga-SDYD07-1 in tumor-bearing mice. DETAILED DESCRIPTION
[0305] To make the objectives, technical solutions, and advantages of the present invention more clearly understood, the present invention will be further described in detail below with reference to the following examples. The specific embodiments described herein are intended only to illustrate the present invention and are not intended to limit the present invention in any way. In addition, in the following description, descriptions of known structures and technologies are omitted to avoid unnecessary confusion about the concepts of the present disclosure. Such structures and technologies are also described in many publications.
[0306] definition
[0307] Unless otherwise defined, all technical and scientific terms used in the present invention have the same meaning as commonly used in the field to which the present invention belongs. For the purpose of interpreting this specification, the following definitions will apply, and where appropriate, terms used in the singular will also include the plural form, and vice versa.
[0308] Unless the context clearly dictates otherwise, as used herein, the expressions "a" and "an" include plural references. For example, reference to "a cell" includes a plurality of such cells and equivalents thereof known to those skilled in the art, and so forth.
[0309] The term "pharmaceutically acceptable salt" refers to a salt of a compound of the invention. Suitable pharmaceutically acceptable salts of the compounds of the invention include acid addition salts, which can be formed, for example, by mixing a solution of choline or a derivative thereof with a solution of a pharmaceutically acceptable acid such as hydrochloric acid, sulfuric acid, fumaric acid, maleic acid, succinic acid, acetic acid, benzoic acid, citric acid, tartaric acid, carbonic acid or phosphoric acid. In addition, when the compound of the invention carries an acidic moiety, suitable pharmaceutically acceptable salts thereof may include alkali metal salts (e.g., sodium or potassium salts); alkaline earth metal salts (e.g., calcium or magnesium salts); and salts formed with suitable organic ligands (e.g., using counter anions such as halides, hydroxides, carboxylates, sulfates, phosphates, nitrates, alkyl sulfonates and aryl sulfonates with ammonium, quaternary ammonium and amine cations). Illustrative examples of pharmaceutically acceptable salts include, but are not limited to, acetate, adipate, alginate, ascorbate, aspartate, benzenesulfonate, benzoate, bicarbonate, bisulfate, bitartrate, borate, bromide, butyrate, edetate, camphorate, camphorsulfonate, camsylate, carbonate, chloride, citrate, clavulanate, cyclopentanepropionate, digluconate, dihydrochloride, lauryl sulfate, edetate, edisylate, estradiol, esylate, ethansulfonate, esulfonate), formate, fumarate, gluconate, glucoheptonate, gluconate, glutamate, glycerophosphate, glycolyl arsanoate, hemisulfate, heptanoate, hexanoate, hexylresorcinate, hydrazine, hydrobromide, hydrochloride, hydroiodide, 2-hydroxyethanesulfonate, hydroxynaphthoate, iodide, isothiocyanate, lactate, lactalate, laurate, lauryl sulfate, malate, maleate, malonate, mandelate, methanesulfonate, methanesulfonate, methylsulfate, mucinate, 2-naphthalenesulfonate, naphthalenesulfonate, nicotinate, nitrate, N-methylglucamine ammonium salt, oleate, The invention also includes but is not limited to the following: oxalate, pamoate (enbolate), palmitate, pantothenate, pectinate, persulfate, 3-phenylpropionate, phosphate / diphosphate, picrate, pivalate, polygalacturonate, propionate, salicylate, stearate, sulfate, subacetate, succinate, tannate, tartrate, theocylate, tosylate, triethyl iodide, undecanoate, valerate, and the like (see, for example, Berge, SM et al., "Pharmaceutical Salts," Journal of Pharmaceutical Science, 1977, 66, 1-19). Certain specific compounds of the present invention contain both basic and acidic functional groups, which allows the compounds to be converted into either base or acid addition salts.
[0310] The neutral form of the compound can be regenerated by contacting the salt with a base or acid and isolating the parent compound in a conventional manner. The parent form of the compound differs from the various salt forms in certain physical properties, such as solubility in polar solvents, but for the purposes of the present invention, these salts are equivalent to the parent form of the compound.
[0311] In addition to the salt form, the present invention provides compounds in the form of prodrugs. Prodrugs of the compounds described herein are those compounds that are susceptible to chemical changes under physiological conditions to provide compounds of formula (I). Prodrugs are active or inactive compounds that are chemically modified into compounds of the present invention by physiological actions such as hydrolysis, metabolism, etc. in vivo after the prodrug is administered to a patient. In addition, prodrugs can be converted into compounds of the present invention by chemical or biochemical methods in an in vitro environment. For example, when the prodrug is placed in a transdermal patch reservoir together with a suitable enzyme, it can be slowly converted into a compound of the present invention. The applicability and technology involved in preparing and using prodrugs are well known to those skilled in the art. For a general discussion of prodrugs involving esters, see Svensson and Tunek, Drug Metabolism Reviews (drug metabolism review) 16.5 (1988) and Bundgaard Design of Prodrugs, Elsevier (1985). Examples of masked carboxylate anions include various esters, such as alkyl (e.g., methyl, ethyl), cycloalkyl (e.g., cyclohexyl), aralkyl (e.g., benzyl, p-methoxybenzyl), and alkylcarbonyloxyalkyl (e.g., pivaloyloxymethyl). Amines have been masked as arylcarbonyloxymethyl-substituted derivatives, which are cleaved in vivo by esterases, releasing free drug and formaldehyde (Bungaard J. Med. Chem. 2503 (1989)). Similarly, drugs containing acidic NH groups, such as imidazoles, imides, indoles, etc., have been masked with N-acyloxymethyl groups (Bundgaard Design of Prodrugs, Elsevier (1985)). Hydroxyl groups have been masked as esters and ethers. EP 0 039 051 (Sloan and Little, April 11, 1981) discloses Mannich-based hydroxamic acid prodrugs, their preparation, and use.
[0312] The term "alkyl" refers to a saturated straight or branched carbon chain. Preferably, the chain contains 1 to 10 carbon atoms, i.e., 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 carbon atoms, such as methyl, ethylmethyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl, pentyl, hexyl, amyl or octyl. Alkyl groups are optionally substituted.
[0313] The term "cycloalkyl" refers to a cyclized alkyl group, including a monocyclic, bicyclic or polycyclic ring system, which does not contain unsaturated bonds such as double bonds and does not contain any heteroatoms, such as C 5-7 Cycloalkyl, C 3-C7 Cycloalkyl or C3-C6 Cycloalkyl. C 5-7 Cycloalkyl groups include C5, C6 and C7 cycloalkyl groups. Examples of cycloalkyl groups include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and the like.
[0314] The term "heteroalkylene" refers to a group in which one or more carbon atoms in a divalent saturated straight or branched chain alkyl group are replaced by a heteroatom. Preferably, the heteroatom is selected from N, O, and S. Preferably, the group contains 1 to 9 carbon atoms, i.e., 1, 2, 3, 4, 5, 6, 7, 8, or 9 carbon atoms. For example, -O-CH2-, -S-CH2-, -CH2-O-CH2-, -CH2-O-C2H4-, -CH2-S-CH2-, -CH2-S-C2H4-, -C2H4-O-CH2-, -C2H4-O-C2H4-, -C2H4-S-CH2-, -C2H4-S-C2H4-, etc. Heteroalkylene is optionally substituted.
[0315] The terms "alkenyl" and "cycloalkenyl" refer to chains or rings containing ethylenically unsaturated carbon atoms with one or more double bonds. Examples are propenyl and cyclohexenyl. Preferably, the alkenyl chain contains 2 to 8 carbon atoms, i.e., 2, 3, 4, 5, 6, 7 or 8 carbon atoms, such as vinyl, 1-propenyl, 2-propenyl, isopropenyl, 1-butenyl, 2-butenyl, 3-butenyl, isobutenyl, sec-butenyl, 1-pentenyl, 2-pentenyl, 3-pentenyl, 4-pentenyl, hexenyl, pentenyl, octenyl. Preferably, the cycloalkenyl ring contains 3 to 8 carbon atoms, i.e., 3, 4, 5, 6, 7 or 8 carbon atoms, such as 1-cyclopropenyl, 2-cyclopropenyl, 1-cyclobutenyl, 2-cyclobutenyl, 1-cyclopentenyl, 2-cyclopentenyl, 3-cyclopentenyl, cyclohexenyl, cyclopentenyl, cyclooctenyl. The term "heteroalkenyl" or "cycloheteroalkenyl" means "alkenyl" or "cycloalkenyl" with one or more heteroatoms inserted therein; preferably, the heteroatoms are selected from N, O, and S.
[0316] The term "alkynyl" refers to a chain or ring containing unsaturated carbon atoms with one or more than one triple bond. An example is propargyl. Preferably, the alkynyl chain contains 2 to 8 carbon atoms, i.e., 2, 3, 4, 5, 6, 7 or 8 carbon atoms, for example, ethynyl, 1-propynyl, 2-propynyl, 1-butynyl, 2-butynyl, 3-butynyl, 1-pentynyl, 2-pentynyl, 4-pentynyl, hexynyl, pentynyl, octynyl.
[0317] The term "aryl" preferably refers to an aromatic monocyclic or polycyclic aromatic ring system containing 5 to 16 carbon atoms, wherein the polycyclic aromatic ring system may be a linked, fused, or spirocyclic aromatic group. Examples are phenyl, biphenyl, naphthyl, or anthracenyl. Aryl groups are optionally substituted.
[0318] The term "aralkyl" refers to an alkyl moiety substituted with an aryl group, wherein alkyl and aryl have the above-mentioned meanings. An example is benzyl. Preferably, in this context, the alkyl chain contains 1 to 8 carbon atoms, i.e., 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms, such as methyl, ethylmethyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butenyl, tert-butyl, pentyl, hexyl, amyl, octyl. The alkyl and / or aryl moieties of the aralkyl group are optionally substituted.
[0319] The term "heteroaryl" refers to a monocyclic or polycyclic aromatic compound in which one or more ring carbon atoms are replaced by heteroatoms; for example, it can be a five-membered or six-membered aromatic monocyclic ring in which at least one ring carbon atom is replaced by 1, 2, 3 or 4 (for a five-membered ring) or 1, 2, 3, 4 or 5 (for a six-membered ring) identical or different heteroatoms, preferably selected from O, N and S; an aromatic bicyclic ring system in which 1, 2, 3, 4, 5 or 6 of the 8, 9, 10, 11 or 12 carbon atoms are replaced by identical or different heteroatoms, preferably selected from O, N and S; or an aromatic tricyclic ring system in which 1, 2, 3, 4, 5 or 6 of the 13, 14, 15 or 16 carbon atoms are replaced by identical or different heteroatoms, preferably selected from O, N and S. Polycyclic ring systems with more than three rings are also possible. The bicyclic, tricyclic or polycyclic ring system may be a linked, fused or spirocyclic aromatic group.
[0320] The term "heteroaralkyl" refers to an alkyl moiety substituted with heteroaryl, wherein alkyl and heteroaryl have the meanings as described above. Examples include 2-alkylpyridyl, 3-alkylpyridyl or 2-picoline. Preferably, the alkyl chain contains 1 to 8 carbon atoms, i.e. 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms, in this context, such as methyl, ethylmethyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butenyl, tert-butyl, amyl, hexyl, amyl, octyl. The alkyl and / or heteroaryl moieties of the heteroaralkyl group are optionally substituted.
[0321] The term "N-containing aromatic or non-aromatic monocyclic or bicyclic heterocycle" refers to a cyclic saturated or unsaturated hydrocarbon compound containing at least one nitrogen atom as a ring chain constituent unit.
[0322] The term "halogen" refers to a halogen residue selected from F, Br, I and Cl. Preferably, halogen is F.
[0323] The term "hydroxy" refers to -OH.
[0324] The expression "optionally substituted" means that one, two, three or more than three hydrogen atoms in the group may be replaced independently of one another by respective substituents.
[0325] In this application, regarding -U 1 -G 1 -A 1 -LA 2 -G 2 -U 2 -, when U 1 , G 1 、A 1 , L, A 2 , G 2 、U 2 When one or more of them are keys, it means that the one or more do not exist. For the sake of clarity, an example is given here, for example, when U 1 When -U is a key, 1 -G 1 -A 1 -LA 2 -G 2 -U 2 - means the same thing as -G 1 -A 1 -LA 2 -G 2 -U 2 -same (i.e., the two are equivalent); when L is a bond, -U 1 -G 1 -A 1 -LA 2 -G 2 -U 2 - means the same thing as -U 1 -G 1 -A 1 -A 2 -G 2 -U 2 Same (i.e., the two are equivalent); when U 1 and G 1 When both are keys, -U 1 -G 1 -A 1 -LA 2 -G 2 -U 2 - means the same thing as -A 1 -LA 2 -G 2 -U2 -same (i.e., the two are equivalent); when U 1 and G 2 When both are keys, -U 1 -G 1 -A 1 -LA 2 -G 2 -U 2 - means the same thing as -G 1 -A 1 -LA 2 -U 2 -same (i.e., the two are equivalent); when U 1 , G 1 and A 1 When both are keys, -U 1 -G 1 -A 1 -LA 2 -G 2 -U 2 -with-LA 2 -G 2 -U 2 -same (i.e., the two are equivalent); when U 1 , G 1 、A 1 , L, A 2 , G 2 When both are keys, -U 1 -G 1 -A 1 -LA 2 -G 2 -U 2 - means the same thing as -U 2 - the same (i.e., the two are equivalent).
[0326] As used herein, the term "amino acid" refers to any organic acid containing one or more than one amino substituent, such as an α-, β-, or γ-amino derivative of an aliphatic carboxylic acid. In the polypeptide notation used herein, for example, Xaa1-Xaa2-Xaa3-Xaa4-Xaa5, wherein Xaa1 to Xaa5 are each independently selected from the defined amino acids; according to standard usage and convention, the left-hand direction is the amino terminal direction and the right-hand direction is the carboxyl terminal direction.
[0327] The term "conventional amino acids" refers to 20 naturally occurring amino acids and includes all stereoisomers thereof, i.e., D, L-, D- and L-amino acids. These conventional amino acids may also be referred to herein by their conventional three-letter or one-letter abbreviations, and their abbreviations follow conventional usage (see, e.g., Immunology—A Synthesis, Second Edition, ES Golub and DR Gren, eds., Sinauer Associates, Sunderland Mass (1991)).
[0328] The term "unconventional amino acid" refers to non-natural amino acids or chemical amino acid analogs, such as α,α-disubstituted amino acids, N-alkyl amino acids, homoamino acids, dehydrogenated amino acids, aromatic amino acids (except phenylalanine, tyrosine, and tryptophan), and o-, m-, or p-aminobenzoic acids. Unconventional amino acids also include compounds with amine and carboxyl functional groups separated by a 1,3 or greater substitution pattern, such as β-alanine, γ-aminobutyric acid, Freidinger lactam, bicyclic dipeptide (BTD), amino-methylbenzoic acid, and others known in the art. Statine-type isosteres, hydroxyethylene isosteres, reduced amide bond isosteres, thioamide isosteres, urea isosteres, carbamate isosteres, thioether isosteres, vinyl isosteres, and other amide bond isosteres known in the art can also be used. Using analogs or unconventional amino acids can improve the stability and biological half-life of the added peptide because they are more resistant to degradation under physiological conditions. Those skilled in the art will recognize that similar types of substitutions can be made. A non-limiting list of unconventional amino acids that can be used as suitable building blocks for peptides and their standard abbreviations (in parentheses) is as follows: α-aminobutyric acid (Abu), LN-methylalanine (Nmala), α-amino-α-methylbutyrate (Mgabu), LN-methylarginine (Nmarg), aminocyclopropane (Cpro), LN-methylasparagine (Nmasn), LN-methylaspartic acid carboxylate (Nmasp), aniline isobutyric acid (Aib), LN-methylcysteine (Nmcys), aminonorbornyl (Norb), LN-methylglutamine (Nmgln), LN-methylglutamic acid carboxylate (Nmglu), Cyclohexylalanine (Chexa), LN-methylhistidine (Nmhis), cyclopentylalanine (Cpen), LN-methylisoleucine (Nmile), LN-methylleucine (Nmleu), LN-methyllysine (Nmlys), LN-methylmethionine (Nmmet), LN-methylnorleucine (Nmnle), LN-methylnorvaline (Nmnva), LN-methylornithine (Nmorn), LN-methylphenylalanine (Nmphe), LN-methyl Proline (Nmpro), LN-methylserine (Nmser), LN-methylthreonine (Nmthr), LN-methyltryptophan (Nmtrp), D-ornithine (Dorn), LN-methyltyrosine (Nmtyr), LN-methylvaline (Nmval), LN-methylethylglycine (Nmetg), LN-methyltert-butylglycine (Nmtbug), L-norleucine (NIe), L-norvaline (Nva), α-methylaminoisobutyrate (Maib),α-Methyl-γ-aminobutyrate (Mgabu), D-α-methylalanine (Dmala), α-methylcyclohexylalanine (Mchexa), D-α-methylarginine (Dmarg), α-methylcyclopentylalanine (Mcpen), D-α-methylasparagine (Dmasn), α-methyl-α-naphthylalanine (Manap), D-α-methylaspartic acid (Dmasp), α-methylpenicillamine (Mpen), D-α-methylcysteine (Dmcys), N-(4-aminobutyl)glycine (NgIu), D-α-methylglutamine (Dmgln), N-(2-aminoethyl)glycine (Naeg), D-α-methylhistidine Acid (Dmhis), N-(3-aminopropyl)glycine (Norn), D-α-methylisoleucine (Dmile), N-amino-α-methylbutyrate (Nmaabu), D-α-methylleucine (Dmleu), α-naphthylalanine (Anap), D-α-methyllysine (Dmlys), N-benzylglycine (Nphe), D-α-methylmethionine (Dmmet), N-(2-carbamoylethyl)glycine (NgIn), D-α-methylornithine (Dmorn), N-(carbamoylmethyl)glycine (Nasn), D-α-methylphenylalanine (Dmphe), N-(2-carboxyethyl)glycine (NgIu), D-α-methylproline (Dmpro), N-(carboxymethyl)glycine (Nasp), D-α-methylserine (Dmser), N-cyclobutylglycine (Ncbut), D-α-methylthreonine (Dmthr), N-cycloheptylglycine (Nchep), D-α-methyltryptophan (Dmtrp), N-cyclohexylglycine (Nchex), D-α-methyltyrosine (Dmty), N-cyclodecylglycine (Ncdec), D-α-methylvaline (Dmval), N-cyclododecylglycine (Ncdod), DN-methylalanine (Dnmala), N-cyclooctylglycine (Ncoct), DN-methylarginine (Dnm arg), N-cyclopropylglycine (Ncpro), DN-methylasparagine (Dnmasn), N-cycloundecylglycine (Ncund), DN-methylaspartic acid (Dnmasp), N-(2,2-diphenylethyl)glycine (Nbhm), DN-methylcysteine (Dnmcys), N-(3,3-diphenylpropyl)glycine (Nbhe), DN-methylglutamine (Dnmgln), N-(3-guanidinopropyl)glycine (Narg), DN-methylglutamic acid (Dnmglu), N-(1-hydroxyethyl)glycine (Ntbx), DN-methylhistidine (Dnmhis), N-(hydroxyethyl))glycine (Nser),DN-methylisoleucine (Dnmile), N-(imidazolylethyl)glycine (Nhis), DN-methylleucine (Dnmleu), N-(3-indolylethyl)glycine (Nhtrp), DN-methyllysine (Dnnilys), N-methyl-γ-aminobutyrate (Nmgabu), N-methylcyclohexylalanine (Nmchexa), DN-methylmethionine (Dnmmet), DN-methylornithine (Dnmorn), N-methylcyclopentylalanine (Nmcpen), N-methylglycine (NaIa), DN-methylphenylalanine (Dnmphe), N-methylaminoisobutyrate (Nmaib), DN-methyl N-methylproline (Dnmpro), N-(1-methylpropyl)glycine (Nile), DN-methylserine (Dnmser), N-(2-methylpropyl)glycine (Nleu), DN-methylthreonine (Dnmthr), DN-methyltryptophan (Dnmtrp), N-(1-methylethyl)glycine (Nval), DN-methyltyrosine (Dnmtyr), N-methyl-α-naphthylalanine (Nmanap), DN-methylvaline (Dnmval), N-methylpenicillamine (Nmpen), γ-aminobutyric acid (Gabu), N-(p-hydroxyphenyl)glycine (Nhtyr), L- / -butylglycine (Tbug), N- (Thiomethyl)glycine (Ncys), L-ethylglycine (Etg), penicillamine (Pen), L-homophenylalanine (Hphe), L-α-methylalanine (Mala), L-α-methylarginine (Marg), L-α-methylasparagine (Masn), L-α-methylaspartic acid (Masp), L-α-methyltert-butylglycine (Mtbug), L-α-methylcysteine (Mcys), L-methylethylglycine (Metg), L-α-methylglutamine (MgIn), L-α-methylglutamate (MgIu), L-α-methylhistidine (Mhis), L-α-methylhomophenylalanine (Mhphe), L-α-methyl Isoleucine (Mile), N-(2-methylthioethyl)glycine (Nmet), L-α-methylleucine (Mleu), L-α-methyllysine (Mlys), L-α-methylmethionine (Mmet), L-α-methylnorleucine (MnIe), L-α-methylnorvaline (Mnva), L-α-methylornithine (Morn), L-α-methylphenylalanine (Mphe), L-α-methylproline (Mpro), L-α-methylserine (Mser), L-α-methylthreonine (Mthr), L-α-methyltryptophan (Mtrp), L-α-methyltyrosine (Mtyr), L-α-methylvaline (Mval),LN-methylhomophenylalanine (Nmhphe), N-(N-(2,2-diphenylethyl)carbamoylmethyl)glycine (Nnbhm), N-(N-(3,3-diphenylpropyl)-carbamoylmethyl)glycine (Nnbhe), 1-carboxy-1-(2,2-diphenyl-ethylamino)cyclopropane (Nmbc), LO-methylserine (Omser), LO-methylhomoserine (Omhser).
[0329] The term "radioactive moiety" refers to a molecular assembly that carries a radionuclide. The nuclide is bound by a covalent or coordinate bond that remains stable under physiological conditions. Examples are [131I]-3-iodobenzoic acid or 68 Ga-DOTA.
[0330] "Fluorescent isotopes" emit electromagnetic radiation upon excitation by electromagnetic radiation of shorter wavelength.
[0331] A "radioisotope" is a radioactive isotope of an element (including within the term "radionuclide") that emits alpha-, beta- and / or gamma-radiation.
[0332] The term "radiopharmaceutical" as used in the context of the present invention refers to a biologically active compound modified with a radioactive isotope. In particular, intercalating substances can be used to deliver radioactivity directly into access to DNA (e.g., 131I-carrying derivatives of Hoechst-33258).
[0333] The chelating group is part of a compound of the invention, wherein the chelating group is directly or indirectly (e.g., via a linker) attached to the compound of the invention. Preferably, the chelating group is a chelating agent that can form a metal chelate, preferably, the metal is at least one radioactive metal. The at least one radioactive metal is preferably useful or suitable for diagnostic and / or therapeutic and / or theranostic applications, more preferably useful or suitable for imaging and / or radiotherapy.
[0334] The term "chelating group" is derived from the term chelating compound. "Chelating agent" or "chelate" are used interchangeably in the context of the present invention and refer to a molecule, typically an organic molecule, usually a Lewis base, having two or more unshared electron pairs that can be donated to a metal ion. The metal ion is typically coordinated to the chelating agent via two or more electron pairs. The terms "bidentate chelator," "tridentate chelator," and "quadridentate chelator" refer to chelating agents having two, three, and four electron pairs, respectively, which are readily donated simultaneously to the metal ion coordinated by the chelating agent. Typically, the electron pairs of the chelating agent form coordination bonds with a single metal ion. However, in some instances, the chelating agent can form coordination bonds with more than one metal ion, and a variety of binding modes are possible.
[0335] In principle, chelating agents that can be used for and / or are applicable to the practice of the present invention (including diagnosis and / or treatment of disease) are known to those skilled in the art. Various corresponding chelating agents are available and have been reviewed, such as Banerjee et al. (Banerjee, et al., Dalton Trans, 2005, 24: 3886) and references therein (Price, et al., Chem Soc Rev, 2014, 43: 260; Wadas, et al., Chem Rev, 2010, 110: 2858). Such chelating agents include but are not limited to linear, cyclic, macrocyclic, tetrapyridine, N3S, N2S2 and N4 chelating agents, such as US 5,367,080 A, US 5,364,613 A, US 5,021,556 A, US 5,075,099 A and US 5,886,142 A.
[0336] Representative chelating agents and their derivatives include, but are not limited to, AAZTA, BAT, CDTA, DTA, DTPA, CY-DTA, DTCBP, CT A, cyclam, cyclen, TETA, Sarcophagine, CPTA, TEAMA, Cyclen, DO3A, DO2A, TRITA, DATA, DFO, DATA(M), DATA(P), DATA(Ph), DATA(PPh), DEDPA, H4octapa, H2dedpa, H5decapa, H2azapa, H2CHX DEDPA, DFO-Chx-MAL, DFO-p-SCN, DFO-1AC, DFO-BAC, p-SCN-Bn-DFO, DFO-pPhe-NCS, DFO-HOPO, DFC, Diphosphine, DOTA, DOTAGA, DOTA-MFCO, DOTAM-monobasic acid, nitro-DOTA, nitro-PA-DOTA, p-NC S-Bz-DOTA, PA-DOTA, DOTA-NCS, DOTA-NHS, CB-DO2A, PCTA, p-NH2-Bn-PCTA, p-SCN-Bn-PCTA, p-SCN-Bn-DOTA, DOTMA, NB-DOTA, H4NB-DOTA, H4TCE-DOTA, 3,4,3-(Li-1,2-HOPO), TREN(Me-3,2-HOPO), TCE-DOTA, DOTP, DOXP, p-NCS-DOTA, p-NCS-TRITA, TRITA, TETA, 3p-C-DEPA, 3p-C-DEPA-NCS, p-NH2-BN-OXO-DO3A, p-SCN-BN-TCMC, TCMC, 4-aminobutyl-DOTA, azido-monoamide-DOTA, BCN-DOTA, butyne-DOTA, BCN-DOTA-GA, DOA3P, DO2a2p, DO2 A(trans-H2do2a), DO3A, DO3A-thiol, DO3AtBu-N-(2-aminoethyl)acetamide, DO2AP, CB-DO2A, C3B-DO2A, HP-DO3A, DOTA-NHS-ester, maleimide-DOTA-GA, maleimido-mono-amide-DOTA, maleimide-DOTA, NH2-DOTA-GA, NH2-PEG4-DOTA-GA, GA, p-NH2-Bn-DOTA, p-NO2-Bn-DOTA, p -SCN-Bn-DOTA, p-SCN-Bz-DOTA, TA-DOTA, TA-DOTA-GA, OTTA, DOXP, TSC, DTC, DTCBP, PTSM, ATSM, H2ATSM, H2PTSM, Dp44mT, DpC, Bp44mT, QT, hybrid thiosemicarbazone–benzothiazole, thiosemicarbazone–styrylpyridine tetradentate ligand H2L2–4, HBED, HBED-CC, dmHBED, dmEHPG, HBED-nn, SHBED, Br-Me2HBED, BPCA, HEHA, BF-HEHA, Deferiprone, THP, HYNIC (2-hydrazinonicotinamide), NHS-HYNIC, HYNIC-Kp-DPPB, HYNIC-Ko-DPPB, (HYNIC)(tricine)2, (HYNIC)(EDDA)Cl, p-EDDHA, AIM, AIM A,IAM B, MAMA, MAMA-DGal, MAMA-MGal, MAMA-DA, MAMA-HAD, Macropa, Macropaquin, Macroquin-SO3, N, x S 4-x, N2S2, N3S, N4, MAG3B, NOTA, NODAGA, SCN-Bz-NOTA-R, NOT-P(NOTMP), NOTAM, p-NCS-NOTA, TACN, TACN-TM, NETA, NETA-monoamine, p-SCN-PhPr-NE3TA, C-NE3TA-NCS, C-NETA-NCS, 3p-C-NETA, NODASA, NOPO, NODA, NO2A, N-Benzyl-NODA, C-NOTA, BCNOT-monoamine, maleimido-mono-amide-NOTA, NO2A-azide , NO2A-butyne, NO2AP, NO3AP, N-NOTA, oxo-DO3A, p-NH2-Bn-NOTA, p-NH2-Bn-oxo-DO3A, p-NO2-Bn-Cyclen, p-SCN-Bn-NOTA, p-SCN-Bn-oxo-DO3A, T RAP, PEPA, BF-PEPA, Pycup, Pycup2A, pycup1A1Bn, pycup2Bn, SarAr-R, Diamsar, AmBaSar-R, siamSar, Sar, Tachpyr, tachpyr-(6-Me), TAM A.TAM B. TAME, TAME-Hex, THP-Ph-NCS, THP-NCS, THP-TATE, NTP, H3THP, THPN, CB-TE2A, PCB-TE1A1P, TETA-NHS, CPTA, CPTA-NHS, CB-TE1K1P, CB-TE2A, TE2A, H2CB-TE2A, TE2P, CB-TE2P, MM-TE2A, DM-TE2A, 2C-TETA, 6C-TETA, BAT, BAT-6, NHS-BAT ester, SSBAT, SCN-CHX-A-DTPA-P, SCN-TETA, TMT-amine, p-BZ-HTCPP.
[0337] HYNIC, DTPA, EDTA, DOTA, TETA, bisaminobisthiol (BAT)-based chelators are disclosed in US 5,720,934; deferoxamine (DFO) is disclosed in (Doulias, et al., Free Radic Biol Med, 2003, 35:719), tetrapyridine and N3S, N2S2 and N4 chelators are disclosed in US 5,367,080 A, US 5,364,613 A, US 5,021,556 A, US 5,075,099 A, US 5,886,142 A, all of which are incorporated herein by reference in their entirety. 6-Amino-6-methylperhydro-1,4-diazepane-N,N′,N″,N″-tetraacetic acid (AAZTA) was disclosed in Pfister et al. (Pfister, et al., EJNMMI Res, 2015, 5:74), deferiprone, i.e., 1,2-dimethyl-3,4-hydroxypyridone, and hexadentate tris(3,4-hydroxypyridone)THP) were disclosed in Cusnir et al. (Cusnir, et al., Int J Mol Sci, 2017, 18), monoamine-monoamidedithiol (MAMA)-based chelators were disclosed in Demoin et al. (Demoin, et al., Nucl Med Biol, 2016, 43:802), MACROPA and its analogs were disclosed in Thiele et al. (Thiele, et al., Angew Chem Int Ed Engl, 2017, 56: 14712), 1,4,7,10,13,16-hexaazacyclohexadecane-N,N′,N″,N″′,N″″,N″″′-hexaacetic acid (HEHA) and PEPA analogs were disclosed in Price and Orvig (Price, et al., ChemSoc Rev, 2014, 43: 260), Pycup and analogs were disclosed in Boros et al. (Boros, et al., Mol Pharm, 2014, 11: 617), disclosed in N,N-bis(2-hydroxybenzyl)ethylenediamine-N,N-diacetic acid (HBED), 1,4,7,10-tetrakis(carbamoylmethyl)-l,4,7,10-tetraazacyclododecane (TCM), 2-[(carboxymethyl)]-[5-(4-nitrophenyl-1-[4,7,10-tris-(carboxymethyl)-1,4,7,10-tetraazacyclododec-1-yl]pentan-2-yl)-amino]acetic acid (3p-C-DEPA), CB-TE2A, TE2A, TE1A1P, Diamsar, 1-N-(4-aminobenzyl)-3,6,10,13,16,19-hexaazabicyclo[6.6.6]-eicosane-1,8-diamine (SarAr), NETA, N,N0,N00 tris(2-mercaptoethyl)-1,4,7-triazacyclononane (TACN-TM), {4-[2-(bis-carboxymethyl-amino)-ethyl]-7-carboxymethyl-[1,4,7]triazanonan-1-yl}-acetic acid (NETA), diethylenetriaminepentaacetic acid (DTP), 3-({4,7-bis-[(2-carboxymethyl-ethyl)-hydroxy-phosphorylmethyl]-[1,4,7]triazacyclononane-1-yl}-acetic acid (NETA), Non-1-ylmethyl}-hydroxy-phosphoryl)-propionic acid (TRAP), NOPO, H4octapa, SHBED, BPCA, 3,6,9,15-tetraazabicyclo[9.3.1]-pentadecan-1(15),11,13-triene-3,6,9,-triacetic acid (PCTA) and 1,4,7,10,13-pentaazacyclopentadecan-N,N′,N″,N″′,N″″-pentaacetic acid (PEPA) were prepared in Price and Orvig (Price, et al. al., Chem Soc Rev, 2014, 43:260), 1-hydroxy-2-pyridone ligand (HOPO) was disclosed in Allott et al. (Allott, et al., Chem Commun (Camb), 2017, 53:8529), [4-carboxymethyl-6-(carboxymethyl-methyl-amino)-6-methyl-[1,4]diazepan-1-yl]-acetic acid (DATA) was disclosed in Tornesello et al. (Tornesello, et al., Molecules, 2017, 22:1282), tetrakis(aminomethyl)methane (TAM) and the like were disclosed in McAuley 1988 (McAuley, et al., Canadian Journal of Chemistry, 1989, 67:1657), hexadentate tris(3,4-hydroxypyridone) (THP) and the like were disclosed in Ma et al. (Ma, et al., Dalton Trans, 2015, 44: 4884).
[0338] The prior art describes some of the diagnostic and / or therapeutic applications of the above-mentioned chelators. For example, 2-hydrazinonicotinamide (HYNIC) has been widely used to incorporate 99m Tc and 186,188 Re (Schwartz, et al., Bioconjug Chem, 1991, 2:333; Babich, et al., J Nucl Med, 1993, 34: 1964; Babich, et al., Nucl Med Biol, 1995, 22: 25); DTPA is used Sino-Israeli complex 111In, and some modifications are described in the literature (Li, et al., Nucl Med Biol, 2001, 28:145; Brechbiel, et al., Bioconjug Chem, 1991, 2:187); the use of DOTA-type chelators in radiotherapy is described by Tweedle et al. (US Pat 4,885,363); other polyaza macrocycles that chelate trivalent isotopes of metals are described by Eisenwiener et al. (Eisenwiener, et al., Bioconjug Chem, 2002, 13:530); N4-chelators such as 99m Tc-N4-chelates have been used for peptide labeling in the case of minigastrin targeting the CCK-2 receptor (Nock, et al., J Nucl Med, 2005, 46: 1727).
[0339] In some embodiments, the metal chelator is selected from, but is not limited to, DOTA, DOTAGA, NOTA, NODAGA, NODA-MPAA, HBED, TETA, CB-TE2A, DTPA, DFO, Macropa, HOPO, TRAP, THP, DATA, NOTP, sarcophagine, FSC, NETA, H4octapa, Pycup, N x S 4-x (N4, N2S2, N3S), Hynic, 99m Tc(CO)3-chelating agents and analogs thereof, wherein:
[0340] DOTA stands for 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid; DOTAGA stands for 1,4,7,10-tetraazacyclododecane-1-(pentanedioic acid)-4,7,10-triacetic acid; NOTA stands for 1,4,7-triazacyclononanetriacetic acid; NODAGA stands for 1,4,7-triazacyclononane-N-pentanedioic acid-N',N"-diacetic acid; NODA-MPAA stands for 1,4,7-triazacyclononane-1,4-diacetic acid-methylphenylacetic acid; HBED represents bis(2-hydroxybenzyl)ethylenediaminediacetic acid; TETA represents 1,4,8,11-tetraazacyclododecane-1,4,8,11-tetraacetic acid; CB-TE2A represents 4,11-bis-(carboxymethylmethyl)-1,4,8,11-tetraazabicyclo[6.6.2]-hexadecane; DTPA represents diethylenetriaminepentaacetic acid; DFO represents a chelating agent of the Desferal or Desferrioxamine type, the chemical name of which is a non-limiting example of N-[5- ({3-[5-(acetyl-hydroxy-amino)-pentylcarbamoyl]-propionyl}-hydroxy-amino)-pentyl]-N'-(5-amino-pentyl)-N'-hydroxy-succinamide; Macropa represents N,N'-bis[(6-carboxy-2-pyridyl)methyl]-4,13-diaza-18-crown; HOPO represents an octadecylhydroxypyridone type chelating agent group, the structure of a non-limiting example of which is shown below; TRAP represents 3-({4,7-bis-[(2-carboxy-ethyl)-hydroxy-phosphoryl]- THP represents hexadentate tris(3,4-hydroxypyridinone); DATA represents [4-carboxymethyl-6-(carboxymethyl-methyl-amino)-6-methyl-[1,4]diazepan-1-yl]-acetic acid; NOTP represents 1,4,7-triazacyclononane-N,N′N″-tri(methylenephosphonic) acid); Sarcophagine represents 3,6,10,13,16,19-hexaazabicyclo[6.6.6]eicosane; FSC stands for 3,15,27-triamino-7,19,31-trihydroxy-10,22,34-trimethyl-1,13,25-trioxa-7,19,31-triaza-cyclohexatriacontane-9,21,33-triene-2,8,14,20,26,32-hexaone; NETA, {4-[2-(bis-carboxymethyl-amino)-ethyl]-7-carboxymethyl-[1,4,7]triazanonan-1-yl}-acetic acid; H4 Octapa represents N,N′-(6-carboxy-2-pyridylmethyl)-N,N′-diacetic acid-1,2-ethylenediamine; Pycup represents 1,8-(2,6-pyridyldimethylene)-1,4,8,11-tetraazacyclotetradecane; NxS4-x(N4, N2S2, N3S) represents a group of tetradentate chelating agents with a nitrogen atom (basic amine or non-basic amide) and a thiol donor, which stabilize Tc complexes, particularly Tc(V)-oxo complexes. The structure of a representative, non-limiting example, MAG3, is shown below; and MAG3 represents {2-[2-(3-mercapto-propionylamino)-acetylamino]-acetylamino}-acetic acid; HYNIC represents 6-hydrazino-nicotinic acid. 99m Tc(CO)3-chelator means a bidentate or tridentate chelator that can form a stable complex with a technetium tricarbonyl fragment;
[0341] Its chemical structure is shown below:
[0342] In some embodiments, the metal chelator is selected from DOTA, DOTAGA, NOTA, NODAGA, NODA-MPAA, HBED, CB-TE2A, DFO, THP, N4, and the like.
[0343] In some embodiments, the metal chelator is selected from DOTA, DOTAGA, NOTA, N4Ac, and NODAGA and analogs thereof.
[0344] Those skilled in the art will further appreciate that, unless otherwise stated, the presence of the chelating agent in the compounds of the invention includes the possibility of the chelating agent being complexed with any metal complex partner (i.e., any metal that could theoretically be complexed by the chelating agent). Specific reference to a chelating agent of the compounds of the invention or the general term chelating agent in relation to the compounds of the invention refers to the uncomplexed chelating agent itself, or to a chelating agent bound to any metal complex partner, wherein the metal complex partner is any radioactive or non-radioactive metal complex partner. Preferably, the chelating agent metal complex, i.e., the chelating agent to which the metal complex partner is bound, is a stable chelating agent metal complex.
[0345] Non-radioactive chelating agent metal complexes have multiple applications, for example, for assessing properties that are difficult to determine, such as stability or activity. One aspect is that cold variants of the radioactive form of the metal complex partner (for example, non-radioactive gallium, lutetium or indium complexes described in the embodiments) can serve as substitutes for radioactive compounds. In addition, they are valuable tools for identifying metabolites and assessing the toxicity properties of the compounds of the invention in vitro or in vivo. In addition, chelating agent metal complexes can be used in conjunction with assays, utilizing some metal complexes (for example, europium salts) with different ligands for fluorescence properties.
[0346] Chelating agents can be synthetic or commercially available, with a variety of (possibly activated) groups conjugated to peptides or amino acids. Direct conjugation of a chelating agent to the amino nitrogen of a corresponding compound of the invention is entirely possible for a chelating agent selected from the group consisting of DOTA, DOTAGA, NOTA, NODAGA, NODA-MPAA, HBED, TETA, CB-TE2A, DTPA, DFO, DATA, sarcophagine, N4, MAG3, and Hynic, preferably DOTA, DOTAGA, NOTA, NODAGA, NODA-MPAA, CB-TE2A, and N4. Preferred linkages in this regard are amide bonds.
[0347] Those skilled in the art are aware of functional groups on chelating agents that are ideal precursors for direct conjugation of the chelating agent to the amino nitrogen, including but not limited to carboxylic acids, activated carboxylic acids, for example active esters such as NHS-esters, pentafluorophenol-esters, HOBt-esters and HOAt-esters, isothiocyanates.
[0348] Those skilled in the art are aware of functional groups on chelators that are ideal precursors for direct conjugation of chelators to the carboxyl groups of peptides, including but not limited to alkylamino and arylamino nitrogens. Corresponding chelator reagents are for some commercially available chelators, such as DOTA with alkylamino or arylamino nitrogens.
[0349] The person skilled in the art will recognize that the radionuclide to be or to be linked to the compounds of the invention is selected taking into account the disease to be treated and / or the disease to be diagnosed and / or the characteristics of the patient and patient group to be treated and diagnosed, respectively.
[0350] In some embodiments of the present invention, the radioactive nuclide is also referred to as a radionuclide. Radioactive decay is the process by which the nucleus of an unstable atom loses energy by emitting ionizing particles (ionizing radiation). There are different types of radioactive decay. When an atom with one type of nucleus (called the parent radionuclide) transforms into a nucleus with a different state or containing a different number of protons and neutrons, energy decay or loss results. Any of these products is named a daughter nuclide. In some decays, the parent and daughter are different chemical elements, so the decay process results in nuclear transmutation (the production of atoms of new elements). For example, radioactive decay can be alpha decay, beta decay, and gamma decay. Alpha decay occurs when an atomic nucleus ejects an alpha particle (helium nucleus). This is the most common process of emitting nucleons, but in rarer types of decay, the atomic nucleus can eject protons, or specific nucleons of other elements (in this process is called cluster decay). In the process of protons turning into neutrons or vice versa, in the process of the atomic nucleus emitting electrons (beta decay), the nucleus emits electrons (beta decay). - - decay) or positron (β + - decay) and a type of neutrino, beta decay occurs. In contrast, there are radioactive decay processes that do not result in transmutation. The energy of the excited nucleus can be emitted in the form of gamma rays in gamma decay, or used to eject orbital electrons by interacting with the excited nucleus in a process called internal conversion, or used to absorb internal atomic electrons from electron shells, thereby converting nuclear protons into neutrons, resulting in the emission of electron neutrinos in a process called electron capture (EC), or can be emitted without changing the number of protons and neutrons in a process called isotropic transition (IT). One form of radioactive decay, spontaneous fission (SF), is only found in very heavy chemical elements and results in spontaneous decomposition into smaller atomic nuclei and some isolated nuclear particles. The compounds according to the present invention can be synthesized according to one or more of the following methods. It should be noted that general steps are shown because they relate to the preparation of compounds with unspecified stereochemistry. However, such steps are generally applicable to those compounds with specific stereochemistry, for example, where the stereochemistry of the group is (S) or (R). Additionally, compounds having one stereochemistry (eg, (R)) can generally be used to generate those having the opposite stereochemistry (ie, (S)) using well-known methods, such as by transformation.
[0351] Certain compounds of the present invention may exist in unsolvated forms as well as solvated forms including hydrated forms. Generally speaking, solvated forms are equivalent to unsolvated forms and are intended to be included within the scope of the present invention. Certain compounds of the present invention may exist in a variety of crystalline or amorphous forms. Generally speaking, all physical forms are equivalent for the intended uses of the present invention and are intended to fall within the scope of the present invention.
[0352] Certain compounds of the present invention possess asymmetric carbon atoms (optical centers) or double bonds; the racemates, diastereomers, geometric isomers and individual isomers are encompassed within the scope of the present invention.
[0353] The compounds of the present invention may also contain unnatural proportions of atomic isotopes at one or more atoms that constitute such compounds. For example, radioactive isotopes such as tritium ( 3 H), iodine-125 ( 125 I) or carbon-14 ( 14 C) Radiolabeling of Compounds All isotopic variations of the compounds of the present invention, whether radioactive or not, are intended to be encompassed within the scope of the present invention.
[0354] The term "pharmaceutical composition" as used in this application refers to a substance and / or combination of substances used to identify, prevent or treat a tissue condition or disease. Pharmaceutical compositions are formulated to be suitable for administration to a patient to prevent and / or treat a disease. In addition, a pharmaceutical composition refers to a combination of an active agent and an inert or active carrier that makes the composition suitable for therapeutic use. Pharmaceutical compositions can be formulated for oral, parenteral, topical, inhalation, rectal, sublingual, transdermal, subcutaneous or vaginal administration, depending on their chemical and physical properties. Pharmaceutical compositions include solid, semisolid, liquid, and transdermal therapeutic systems (TTS). Solid compositions are selected from tablets, coated tablets, powders, granules, pills, capsules, effervescent tablets or transdermal therapeutic systems. Liquid compositions are also included, which are selected from solutions, syrups, infusions, extracts, solutions for intravenous administration, solutions for infusions or solutions of the carrier systems of the present invention. Semisolid compositions that can be used in the context of the present invention include emulsions, suspensions, creams, lotions, gels, pellets, buccal tablets and suppositories.
[0355] "Pharmaceutically acceptable" means approved by a regulatory agency of the Federal or a state government or listed in the U.S. Pharmacopeia or other generally recognized pharmacopeia for use in animals, and more specifically in humans.
[0356] The term "carrier" refers to a diluent, adjuvant, excipient, or vehicle used in conjunction with the therapeutic agent. Such pharmaceutical carriers can be sterile liquids, such as saline solutions in water and oil, including those of petroleum, animal, plant, or synthetic origin, such as peanut oil, soybean oil, mineral oil, sesame oil, etc. When the pharmaceutical composition is administered intravenously, saline solutions are preferred carriers. Saline solutions, as well as aqueous glucose solutions and glycerol solutions, can also be used as liquid carriers, particularly for injectable solutions. Suitable pharmaceutical excipients include starch, glucose, lactose, sucrose, gelatin, malt, rice, flour, chalk, silica gel, sodium stearate, glyceryl monostearate, talc, sodium chloride, skim milk powder, glycerol, propylene, ethylene glycol, water, ethanol, etc. If desired, the composition may also contain a small amount of wetting agent or emulsifier or pH buffer. Examples of suitable pharmaceutical carriers are described in "Remington's Pharmaceutical Sciences" by EW Martin.
[0357] Amino acid residues and abbreviations: glutamine Gln, asparagine Asn, histidine His, tryptophan Trp, Tpi, Ala, serine Ser, valine Val, threonine Thr, glycine Gly, sarcosine Sar, D-alanine D-Ala, β-alanine β-Ala, 3-methylhistidine (3-Me) His, phenylalanine Phe, 3-(2-thienyl)alanine Thi, 4-chlorophenylalanine Cpa, tyrosine Tyr, 3-iodo-tyrosine oI-Tyr, pentafluorophenylalanine 5F-Phe
[0358] The term "a group targeting a FAP receptor" refers to one or more molecular structures that are capable of binding to FAP and inhibiting FAP biological activity and / or signaling mediated by FAP.
[0359] The term "a group targeting CXCR4 receptor" refers to one or more than one molecular structure that is capable of binding to CXCR4 and inhibiting CXCR4 biological activity and / or signaling mediated by CXCR4.
[0360] When a substituent is described by a conventional chemical formula written from left to right, the substituent also includes chemically equivalent substituents that would result from writing the formula from right to left. For example,
[0361] Equivalent to
[0362] Equivalent to
[0363] Equivalent to
[0364] Equivalent to
[0365] Equivalent to
[0366] Equivalent to
[0367] Equivalent to
[0368] Equivalent to
[0369] As described herein, the ring system formed by the substituent R being bonded to the central ring (as shown below) means that the substituent R is limited to any substitutable or any reasonable position on Ring A. For example, Formula f represents any possible substitutable position on Ring A, as shown in Formulas f1-f4:
[0370] In the present invention, when a connecting bond runs through a ring system and the other end is connected to the rest of the compound molecule, it means that the bond can be connected to any possible position in the ring system.
[0371] like Represents one of the following structures:
[0372] As described in the present invention, the substituents are connected to the central ring by a bond to form a ring system, such as (R x ) n , representing n substituents R x Substitution can be made at any substitutable position on the ring. For example, formula a represents a benzene ring which can be substituted by n R x replace.
[0373] In the description of this specification, the reference terms "one embodiment", "some embodiments", "example", "specific example", or "some examples" mean that the specific features, structures, materials or characteristics described in conjunction with the embodiment or example are included in at least one embodiment or example of the present invention. In this specification, the schematic representations of the above terms do not necessarily refer to the same embodiment or example. Moreover, the specific features, structures, materials or characteristics described can be combined in any one or more embodiments or examples in a suitable manner. In addition, those skilled in the art can combine and combine different embodiments or examples described in this specification and features of different embodiments or examples without contradiction.
[0374] As used herein, the term "about" refers to a range of ±20% of the value that follows. In some embodiments, the term "about" refers to a range of ±10% of the value that follows. In some embodiments, the term "about" refers to a range of ±5% of the value that follows.
[0375] The following examples and accompanying drawings are provided to facilitate understanding of the present invention. However, it should be understood that these examples and accompanying drawings are intended to illustrate the present invention only and are not intended to limit the present invention in any way. The actual scope of protection of the present invention is set forth in the claims. It should be understood that any modifications and variations may be made without departing from the spirit of the present invention.
[0376] Methods and Materials
[0377] Experimental materials and instruments
[0378] Unless otherwise specified, all chemicals were purchased commercially and used without further purification. Table 1 lists the instruments and important chemicals used in this experiment.
[0379] Table 1 Experimental instruments and materials
[0380] Chromatographic conditions
[0381] The chromatographic conditions used for precursor analysis and radiotracer analysis are shown in Table 2 .
[0382] Table 2 Chromatographic conditions
[0383] Example 1: Synthesis of SDYD01 and related radioactivity experimental studies
[0384] Synthesis and analysis of SDYD01:
[0385] S1. Dissolve 1-1 (100 mg) in 20 mL of DMF, add 6.0 eq of DIPEA, and then add 5.0 eq of 1-2. React at room temperature for 3 hours. Completion of the reaction is monitored by LC-MS. Remove DMF by vortexing, and separate and purify by reverse-phase preparative liquid chromatography to obtain 61 mg of 1-3 (yield: 51%).
[0386] S2. 1-3 (61 mg) was dissolved in 10 mL of DMF, and 1.2 eq DCC and 1.2 eq HOSu were added, and the reaction was carried out at room temperature for 6 hours. The precipitated solid was removed by filtration, and then 296 mg of 1-4 and 2 eq TEA were added to the filtrate, and the reaction was carried out at room temperature for 3 hours. The completion of the reaction was monitored by LC-MS, and the DMF was removed by rotation. The product was separated and purified by reverse phase preparative liquid phase to obtain 188 mg of the target product SDYD01 (yield: 53%).
[0387] The HPLC purity was 97.05%, as shown in Figure 1. The theoretical molecular weight was 3410.93, and the measured [M+4H] / 4 was 853.6, as shown in Figure 2. Elemental analysis showed N% to be 14.65%, C% to be 50.05%, and H% to be 5.89%, consistent with the theoretical values. The main peak PI was 12.474, and the specific rotation was -9.8°.
[0388] Radiolabeling method and radiochemical purity determination of SDYD01
[0389] Radiochemical purity refers to the percentage of radionuclides in a radioactive sample that exist in a specific chemical form. In this experiment, it refers to the percentage of radioactivity successfully labeled on the compound SDYD01 compared to the total radioactivity after purification.
[0390] 1. 68 Ga labeling: 10 μg of compound SDYD01 was added to 100 μL NaOAc (0.25 M) buffer, and then 400 μL 68 GaCl3 solution (0.05M HCl elution 68 Ge- 68 Ga generator), shaken at 100 ° C for 15 min; the crude product was purified by C18 column. Radioactive high performance liquid chromatography was used to determine 68 Radiochemical purity of Ga-SDYD01.
[0391] 2. 177 Lu labeling: 10 μg of compound SDYD01 was added to 150 μL sodium acetate buffer (pH = 4.6), and 20 MBq of 177 LuCl3 solution was shaken at 100℃ for 50min; the crude product was purified by C18 column. Radioactive high performance liquid chromatography was used for determination 177 Radiochemical purity of Lu-SDYD01.
[0392] Radioactive high performance liquid chromatography was used to determine 68 The radiochemical purity of Ga / 177Lu-SDYD01 was determined 68 The radiochemical purity of Ga-SDYD01 is 99%. 177 The radiochemical purity of Lu-SDYD01 was 98% ( FIG. 3 ).
[0393] Stability experiment of SDYD01 radioligand in PBS buffer
[0394] The purpose of this experiment is to test the stability of the radioligand in buffer conditions that simulate the human body. This stability is a prerequisite for further animal studies. If the ligand does not show significant degradation, it indicates that the metal chelation and peptide bond are stable in the buffer.
[0395] 1. 68 Ga-SDYD01: 68 Ga-SDYD01 was added to a PBS buffer solution at pH 7.4 and incubated at 37° C. for 0.5 hour, 1 hour, and 2 hours. Samples of the mixture were then taken for radioactive HPLC analysis. 68 Stability of Ga-SDYD01 in PBS buffer: 68 After incubation in PBS for 0.5 hours, 1 hour, and 2 hours, the radiochemical purity of Ga-SDYD01 was 98%, 97%, and 97%, respectively (Figure 4). 68 Ga-SDYD01 is quite stable in PBS buffer.
[0396] 2. 177 Lu-SDYD01: 177 Lu-SDYD01 was added to a PBS buffer solution at pH 7.4, and incubated at 37° C. for 24, 48, and 120 hours. Samples of the mixture were then taken for radioactive HPLC analysis. 177 Stability of Lu-SDYD01 in PBS buffer: 177 After incubation in PBS for 24 hours, 48 hours, and 120 hours, the radiochemical purity of Lu-SDYD01 was 97%, 96%, and 94%, respectively (Figure 5). 177 Lu-SDYD01 is quite stable in PBS buffer.
[0397] Competition experiment of SDYD01 radioligand against endogenous free amino acids
[0398] In a solution containing 150 μL PBS buffer, 150 μL H2O and 50 μL 68 Add 50 μL of cysteine hydrochloride solution (10 mM) or histidine solution (10 mM) to the Ga-SDYD01 EP tube, vortex the mixture, and incubate at 37°C for 2 hours before taking a sample for radioactive HPLC analysis.
[0399] This study used different concentrations of histidine and cysteine solutions to investigate whether histidine (or cysteine) 68 Ga-SDYD01 has metal chelation competition. 68 After incubation in histidine and cysteine for 2 hours, the radiochemical purity of Ga-SDYD01 was still 93% (Figure 6).68 Ga-SDYD01 does not undergo competitive chelation in the presence of histidine and cysteine.
[0400] Determination of the hydrophilicity and lipophilicity of SDYD01 radioligand
[0401] After purification, 10 μL of 68Ga-SDYD01 was diluted to 500 μL with HEPES buffer (pH 7.4). 500 μL of n-octanol was then added, vortexed for 30 minutes, and centrifuged. 450 μL of each of the aqueous and organic phases were taken and centrifuged again. 100 μL of each was taken from the aqueous and organic phases and the radioactivity count was measured using a gamma counter. The octanol / water partition coefficient (Log Do / w) was calculated. 68 The Log Do / w value of Ga-SDYD01 is -2.54±0.01, 177 The Log Do / w value of Lu-SDYD01 is -2.55±0.05.
[0402] Example 2: Synthesis of SDYD02 and Related Radioactivity Experimental Studies
[0403] Synthesis and analysis of SDYD02:
[0404] S1. Dissolve 2-1 (500 mg) and 2-2 (140 mg) in 5 mL DMF, add 3 eq DIPEA, and react at room temperature for 3 hours. Monitor the reaction by LC-MS. After the reaction is complete, spin-dry the DMF and purify by reverse phase to obtain 320 mg 2-3 (yield 64%).
[0405] S2. Dissolve 2-3 (320 mg) and 2-4 (344 mg) in acetonitrile and water (1:1, 5 mL). Add 0.2 M PBS buffer (pH 7.2) under nitrogen. Incubate at room temperature for 1 hour, monitoring the reaction with LC-MS. After completion of the reaction, reverse phase purification was performed to obtain 338 mg of the desired product, SDYD02, in a 51% yield.
[0406] The HPLC purity was 95.85%, as shown in Figure 7. The theoretical molecular weight was 4237.01, but the measured [M+4H] / 4 was 1060.0 and the [M+5H] / 5 was 848.2, as shown in Figure 8. Elemental analysis showed N% to be 14.29%, C% to be 52.55%, and H% to be 6.125%, consistent with the theoretical values. The main peak PI was 11.183, and the specific rotation was 6.6°.
[0407] Radiolabeling of SDYD02 and determination of radiochemical purity
[0408] Radiochemical purity refers to the percentage of radionuclides in a radioactive sample that exist in a specific chemical form. In this experiment, it refers to the percentage of radioactivity successfully labeled on the compound SDYD02 compared to the total radioactivity after purification.
[0409] 1. 68 Ga labeling: 10 μg of compound SDYD02 was added to 100 μL NaOAc (0.25 M) buffer, and then 400 μL 68 GaCl3 solution (0.05M HCl elution 68 Ge- 68 Ga generator), shaken at 100 ° C for 15 min; the crude product was purified by C18 column. Radioactive high performance liquid chromatography was used to determine 68 Radiochemical purity of Ga-SDYD02.
[0410] 2. 177 Lu labeling: 20 μg of compound SDYD02 was added to 150 μL of sodium acetate buffer (pH = 4.6), and 20 Mbq of 177 Lu in LuCl3 solution was shaken at 100℃ for 50min; the crude product was purified by C18 column. Radioactive HPLC was used to determine 177 Radiochemical purity of Lu-SDYD02.
[0411] After purification on a C18 column, the 68 Ga / 177 The radiochemical purity of Lu-SDYD02 was determined 68 The radiochemical purity of Ga-SDYD02 is 96%. 177 The radiochemical purity of Lu-SDYD02 was 98% ( FIG. 9 ).
[0412] Stability experiment of SDYD02 radioligand in PBS buffer
[0413] The purpose of this experiment is to test the stability of the radioligand in buffer conditions that simulate the human body. This stability is a prerequisite for further animal studies. If the ligand does not show significant degradation, it indicates that the metal chelation and peptide bond are stable in the buffer.
[0414] 1. 68 Ga-SDYD02: will 68 Ga-SDYD02 was added to a PBS buffer solution at pH 7.4 and incubated at 37° C. for 0.5 hour, 1 hour, and 2 hours. Samples of the mixture were then taken for radioactive HPLC analysis. 68 Stability of Ga-SDYD02 in PBS buffer:68 After incubation in PBS for 0.5 hours, 1 hour, and 2 hours, the radiochemical purity of Ga-SDYD02 was 96%, 95%, and 93%, respectively ( FIG. 10 ); 68 Ga-SDYD02 is quite stable in PBS buffer.
[0415] 2. 177 Lu-SDYD02: 177 Lu-SDYD01 was added to a PBS buffer solution at pH 7.4, and incubated at 37° C. for 24, 48, and 120 hours. Samples of the mixture were then taken for radioactive HPLC analysis. 177 Stability of Lu-SDYD02 in PBS buffer: 177 After incubation in PBS for 24 hours, 48 hours, and 120 hours, the radiochemical purity of Lu-SDYD02 was 95%, 91%, and 87%, respectively ( FIG. 11 ). 177 Lu-SDYD02 is quite stable in PBS buffer.
[0416] Competition experiment of SDYD02 radioligand against endogenous free amino acids
[0417] In a solution containing 150 μL PBS buffer, 150 μL H2O and 50 μL 68 Add 50 μL of cysteine hydrochloride solution (10 mM) or histidine solution (10 mM) to the Ga-SDYD02 EP tube, vortex the mixture, incubate at 37°C for 2 hours, and then take a sample of the mixture for radioactive HPLC analysis.
[0418] This study used different concentrations of histidine and cysteine solutions to investigate whether histidine (or cysteine) 68 Ga-SDYD02 has metal chelation competition. 68 After incubation for 2 hours in histidine and cysteine, the radiochemical purity of Ga-SDYD02 was 92% and 91%, respectively (Figure 12). 68 Ga-SDYD02 does not undergo competitive chelation in the presence of histidine and cysteine.
[0419] Determination of the hydrophilicity and lipophilicity of SDYD02 radioligand
[0420] After purification, 10 μL 68Ga-SDYD02 was diluted to 500 μL with HEPES buffer (pH = 7.4), and then 500 μL of n-octanol was added. The mixture was vortexed for 30 minutes and then centrifuged. 450 μL of each of the aqueous and organic phases were taken and centrifuged again. Then 100 μL of each of the aqueous and organic phases was taken out and the radioactivity count was measured using a gamma counter. The octanol / water partition coefficient (Log Do / w) was calculated. 68 The Log Do / w value of Ga-SDYD02 is -2.47±0.03, 177 The Log Do / w value of Lu-SDYD02 is -2.35±0.02.
[0421] Example 3: Synthesis of SDYD05 and Related Radioactivity Experimental Studies
[0422] Synthesis and analysis of SDYD05:
[0423] S1. Dissolve 5-1 (124 mg) and 5-2 (218 mg) in 10 mL of DMF, add 3 eq of DIEA, and quickly add 1.1 eq of HBTU. React at room temperature for 10 minutes. The reaction is monitored by LC-MS. DMF is removed by vortexing, and 30 mL of TFA is added. Stir at room temperature for 2 hours, and then the reaction solution is slowly added to 50 mL of icy ether. A large amount of solid precipitates and the crude product is filtered to obtain 186 mg of 5-3 (yield: 60%).
[0424] S2. 5-3 (186 mg) and 5-4 (91 mg) were dissolved in 5 mL of DMF, and 3 eq of DIEA was added, followed by rapid addition of 1.1 eq of HBTU. The mixture was reacted at room temperature for 10 minutes. The reaction was monitored by LC-MS to confirm completion. The DMF was removed by vortexing, and 50 mL of 25% DEA / THF was added. The mixture was stirred at room temperature for 2 hours, and the solvent was dried to obtain a crude product. The crude product was separated and purified by reverse-phase preparative liquid chromatography to obtain 129 mg of 5-5 (yield: 54%).
[0425] S3. Dissolve 5-5 (129 mg) and 5-6 (9 mg) in 3 mL DMF, add 3 eq DIEA, and react at room temperature for 3 hours. The reaction is monitored by LC-MS. DMF is removed by vortexing, and the compound is separated and purified by reverse phase preparative liquid chromatography to obtain 74 mg of 5-7 (yield: 53%).
[0426] S4. Dissolve 5-7 (74 mg) and 5-8 (35 mg) in 3 mL DMF, add 3 eq DIEA, and quickly add 1.1 eq HBTU. React at room temperature for 10 minutes. Complete the reaction by LC-MS monitoring. Remove DMF by vortexing, add 5 mL TFA, and stir at room temperature for 30 minutes. Then, slowly add the reaction solution to 50 mL icy ether. A large amount of solid precipitates. The crude product is filtered and purified by reverse phase preparative liquid phase separation to obtain 50 mg of the target product SDYD05 (DOTA-FAPI-Pentixafor) (yield: 50%).
[0427] The HPLC purity was 95.10%, as shown in Figure 13. The theoretical molecular weight was 2207.07, with the measured [M+3H] / 3 being 737.0 and [M+4H] / 4 being 552.9, as shown in Figure 14. Elemental analysis showed N% to be 13.36%, C% to be 53.37%, and H% to be 5.93%, consistent with the theoretical values. The peak PI ranged from 6.617 to 7.126, and the specific rotation was 3.8°.
[0428] Radiolabeling of SDYD05 and determination of its radiochemical purity
[0429] Radiochemical purity refers to the percentage of radionuclides in a radioactive sample that exist in a specific chemical form. In this experiment, it refers to the percentage of radioactivity successfully labeled on compound SDYD05 compared to the total radioactivity after purification.
[0430] 1. 68 Ga labeling: 10 μg of compound SDYD05 was added to 100 μL NaOAc (0.25 M) buffer, and then 400 μL 68 GaCl3 solution (0.05M HCl elution 68 Ge- 68 Ga generator), shaken at 100 ° C for 15 min; the crude product was purified by C18 column. Radioactive high performance liquid chromatography was used to determine 68 Radiochemical purity of Ga-SDYD05.
[0431] 2. 177 Lu labeling: 20 μg of compound SDYD05 was added to 150 μL sodium acetate buffer (pH = 4.6), and 20 Mbq of 177 Lu in LuCl3 solution was shaken at 100℃ for 50min; the crude product was purified by C18 column. Radioactive HPLC was used to determine 177 Radiochemical purity of Lu-SDYD05.
[0432] After purification on a C18 column, the68 Ga / 177 The radiochemical purity of Lu-SDYD05 was determined 68 The radiochemical purity of Ga-SDYD05 is 99%. 177 The radiochemical purity of Lu-SDYD05 was 98% ( FIG. 15 ).
[0433] Stability experiment of SDYD05 radioligand in PBS buffer
[0434] The purpose of this experiment is to test the stability of the radioligand in buffer conditions that simulate the human body. This stability is a prerequisite for further animal studies. If the ligand does not show significant degradation, it indicates that the metal chelation and peptide bond are stable in the buffer.
[0435] 1. 68 Ga-SDYD05: 68 Ga-SDYD05 was added to a PBS buffer solution at pH 7.4 and incubated at 37° C. for 0.5 hour, 1 hour, and 2 hours. Samples of the mixture were then taken for radioactive HPLC analysis. 68 Stability of Ga-SDYD05 in PBS buffer: 68 After incubation in PBS for 0.5 hours, 1 hour, and 2 hours, the radiochemical purity of Ga-SDYD05 was 98%, 96%, and 95%, respectively ( FIG. 16 ); 68 Ga-SDYD05 is quite stable in PBS buffer.
[0436] 2. 177 Lu-SDYD05: 177 Lu-SDYD05 was added to a PBS buffer solution at pH 7.4, and incubated at 37° C. for 24, 48, and 120 hours. Samples of the mixture were then taken for radioactive HPLC analysis. 177 Stability of Lu-SDYD05 in PBS buffer: 177 After incubation in PBS for 24 hours, 48 hours, and 120 hours, the radiochemical purity of Lu-SDYD05 was 97%, 96%, and 96%, respectively ( FIG. 17 ). 177 Lu-SDYD05 is quite stable in PBS buffer.
[0437] Competition experiment of SDYD05 radiolabeled ligand against endogenous free amino acids
[0438] In a solution containing 150 μL PBS buffer, 150 μL H2O and 50 μL 68Add 50 μL of cysteine hydrochloride solution (10 mM) or histidine solution (10 mM) to the EP tube of Ga-SDYD05. Vortex the mixture and incubate at 37°C for 2 hours before taking a sample of the mixture for radioactive HPLC analysis. This study used different concentrations of histidine and cysteine solutions to study whether histidine (or cysteine) 68 Ga-SDYD05 has metal chelation competition. 68 After incubation for 2 hours in histidine and cysteine, the radiochemical purity of Ga-SDYD05 was 94% and 95% (Figure 18). 68 Ga-SDYD05 does not undergo competitive chelation in the presence of histidine and cysteine.
[0439] Determination of the hydrophilicity and lipophilicity of SDYD05 radioligand
[0440] After purification, 10 μL 68 Ga-SDYD05 was diluted to 500 μL with HEPES buffer (pH = 7.4), then 500 μL of n-octanol was added, vortexed for 30 minutes, and centrifuged. 450 μL of the aqueous phase and 450 μL of the organic phase were taken and centrifuged again. Then 100 μL of each of the aqueous phase and the organic phase were taken out and the radioactivity count was measured using a gamma counter, and the octanol / water partition coefficient (Log Do / w) was calculated. 68 The Log Do / w value of Ga-SDYD05 is -2.37±0.02, 177 The Log Do / w value of Lu-SDYD05 is -2.46±0.05.
[0441] Example 4: Synthesis of SDYD06 and Related Radioactivity Experimental Studies
[0442] Synthesis and analysis of SDYD06:
[0443] S1. 6-1 (100 mg) was dissolved in 20 mL of DMF, and 1.2 eq of HBTU and 3.0 eq of DIPEA were added. Then, 1.0 eq (178 mg) of 6-2 was added thereto, and the mixture was reacted at room temperature for 2 hours. The reaction was monitored to be complete by LC-MS. The DMF was removed by vortexing, and 20 mL of TFA was added. The mixture was stirred at room temperature for 30 min. The reaction was monitored to be complete by LC-MS. A large amount of solid was precipitated by adding glacial ether, and the solid was centrifuged. The solid was separated and purified by reverse phase preparative liquid phase to obtain 179.8 mg of 6-3 (yield: 71%).
[0444] S2. 6-3 (179.8 mg) was dissolved in 20 mL DMF, and 1.2 eq HBTU and 3.0 eq DIPEA were added, followed by 1.0 eq (173.6 mg) Cmpd4. The mixture was reacted at room temperature for 2 hours. The reaction was completed after monitoring by LC-MS. The DMF was removed by vortexing, and 15 mL THF and 5 mL DEA were added. The mixture was stirred at room temperature for 2 hours. The reaction was completed after monitoring by LC-MS and concentrated. The mixture was separated and purified by reverse phase preparative liquid phase to obtain 168 mg 6-5 (yield: 73%).
[0445] S3. 6-5 (168 mg) was dissolved in 20 mL DMF, and 2.0 eq DIPEA was added, followed by the addition of 3.0 eq (88.4 mg) 6-6. The mixture was reacted at room temperature for 2 hours. The reaction was monitored to be complete by LC-MS. The DMF was removed by vortexing, and 20 mL TFA was added. The mixture was stirred at room temperature for 2 hours. The reaction was monitored to be complete by LC-MS. Glacial ether was added to precipitate a large amount of solid, which was centrifuged. The solid was separated and purified by reverse phase preparative liquid phase to obtain 127.9 mg 6-7 (yield: 77%).
[0446] S4. Dissolve 6-7 (127.9 mg) in 20 mL of H2O / ACN = 1:1, add 1.2 eq (148 mg) of 6-8, and then add 5 mL of 0.2 mol pH = 7.2 PBS Buffe solution. React at room temperature for 1 hour. The reaction is monitored by LC-MS to be complete. The reaction solution is directly separated and purified by reverse phase preparative liquid phase to obtain 150 mg of SDYD06 (yield: 60%).
[0447] The HPLC purity was 99.23%, as shown in Figure 19. The theoretical molecular weight was 2949.44, but the measured [M+3H] / 3 was 983.8 and the [M+4H] / 4 was 738.2, as shown in Figure 20. Elemental analysis showed N% was 12.11%, C% was 51.09%, and H% was 5.76%, consistent with the theoretical values. The specific rotation was -13.5°. When measuring the isoelectric point, insoluble matter was detected in pure water, and no detectable results were found in the supernatant after centrifugation.
[0448] Radiolabeling and radiochemical purity determination of SDYD06
[0449] Radiochemical purity refers to the percentage of radionuclides in a radioactive sample that exist in a specific chemical form. In this experiment, it refers to the percentage of radioactivity successfully labeled on compound SDYD06 compared to the total radioactivity after purification.
[0450] 1. 68 Ga labeling: 10 μg of compound SDYD06 was added to 100 μL NaOAc (0.25 M) buffer, and then 400 μL 68GaCl3 solution (0.05M HCl elution 68 Ge- 68 Ga generator), shaken at 100 ° C for 15 min; the crude product was purified by C18 column. Radioactive high performance liquid chromatography was used to determine 68 Radiochemical purity of Ga-SDYD06.
[0451] 2. 177 Lu labeling: 10 μg of compound SDYD06 was added to 150 μL of sodium acetate buffer (pH = 4.6), and 20 Mbq of 177 Lu in LuCl3 solution was shaken at 100℃ for 50min; the crude product was purified by C18 column. Radioactive HPLC was used to determine 177 Radiochemical purity of Lu-SDYD06.
[0452] After purification on a C18 column, the 68 Ga / 177 The radiochemical purity of Lu-SDYD06 was determined 68 The radiochemical purity of Ga-SDYD06 is 97%. 177 The radiochemical purity of Lu-SDYD06 was 98% ( FIG. 21 ).
[0453] Stability experiment of SDYD06 radioligand in PBS buffer
[0454] The purpose of this experiment is to test the stability of the radioligand in buffer conditions that simulate the human body. This stability is a prerequisite for further animal studies. If the ligand does not show significant degradation, it indicates that the metal chelation and peptide bond are stable in the buffer.
[0455] 1. 68 Ga-SDYD06: will 68 Ga-SDYD06 was added to a PBS buffer solution at pH 7.4 and incubated at 37° C. for 0.5 hour, 1 hour, and 2 hours. Samples of the mixture were then taken for radioactive HPLC analysis. 68 Stability of Ga-SDYD06 in PBS buffer: 68 After incubation in PBS for 0.5 hours, 1 hour, and 2 hours, the radiochemical purity of Ga-SDYD06 was 96%, 94%, and 93%, respectively ( FIG. 22 ). 68 Ga-SDYD06 is quite stable in PBS buffer.
[0456] 2. 177 Lu-SDYD06: 177Lu-SDYD06 was added to a PBS buffer solution at pH 7.4, and incubated at 37° C. for 24 hours, 48 hours, and 120 hours. Samples of the mixture were then taken for radioactive HPLC analysis. 177 Stability of Lu-SDYD06 in PBS buffer: 177 The radiochemical purity of Lu-SDYD06 after incubation in PBS for 24 hours, 48 hours, and 120 hours showed that it was quite stable.
[0457] Competition experiment of SDYD06 radiolabeled ligand against endogenous free amino acids
[0458] In a solution containing 150 μL PBS buffer, 150 μL H2O and 50 μL 68 Add 50 μL of cysteine hydrochloride solution (10 mM) or histidine solution (10 mM) to the EP tube of Ga-SDYD06. Vortex the mixture and incubate at 37°C for 2 hours before taking a sample of the mixture for radioactive HPLC analysis. This study used different concentrations of histidine and cysteine solutions to study whether histidine (or cysteine) 68 Ga-SDYD06 has metal chelation competition. 68 After incubation for 2 hours in histidine and cysteine, the radiochemical purity of Ga-SDYD06 was 92% and 93% (Figure 23). 68 Ga-SDYD06 does not undergo competitive chelation in the presence of histidine and cysteine.
[0459] Determination of the hydrophilicity and lipophilicity of SDYD06 radioligand
[0460] After purification, 10 μL 68 Ga-SDYD06 was diluted to 500 μL with HEPES buffer (pH = 7.4), and then 500 μL of n-octanol was added. The mixture was vortexed for 30 minutes and then centrifuged. 450 μL of each of the aqueous and organic phases were taken and centrifuged again. Then 100 μL of each of the aqueous and organic phases was taken out and the radioactivity count was measured using a gamma counter. The octanol / water partition coefficient (Log Do / w) was calculated. 68 The Log Do / w value of Ga-SDYD06 is -1.84±0.03, 177 The Log Do / w value of Lu-SDYD06 is -1.94±0.08.
[0461] Example 5: Synthesis of SDYD03 and Related Radioactivity Experimental Studies
[0462] Synthesis and analysis of SDYD03:
[0463] S1. 3-1 (300 mg) was dissolved in 10 mL of DMF, and 1.1 eq of EDC and 1.1 eq of HOBt were added, and the mixture was reacted at room temperature for 10 min. 2.0 eq (31.5 mg) of 3-2 and 5.0 eq of N-methylmorpholine were added, and the mixture was reacted at room temperature for 2 hours. The reaction was monitored by LC MS. The DMF was removed by vortexing, and 10 mL of TFA was added. The mixture was stirred at room temperature for 2 hours. A large amount of solid was precipitated with glacial ether, and the solid was centrifuged. The solid was separated and purified by reverse phase preparative liquid chromatography to obtain 127 mg of 3-3 (yield: 58%).
[0464] S2. 3-3 (127 mg) was dissolved in 20 mL of DMF, and 1.2 eq DCC and 1.2 eq HOSu were added and reacted at room temperature for 6 hours. The precipitated solid was removed by filtration, and then 2.0 eq 75 mg of 3-4 and 2.0 eq TEA were added to the filtrate and reacted at room temperature for 3 hours. The completion of the reaction was monitored by LC MS. The DMF was removed by vortexing and the target product SDYD03 (yield: 73%) was obtained by reverse phase preparative liquid phase separation and purification.
[0465] The HPLC purity was 96.38%, as shown in Figure 24. The theoretical molecular weight was 2562.91, with the measured [M+3H] / 3 being 855.1 and [M+4H] / 4 being 641.5, as shown in Figure 25. Elemental analysis showed N% to be 12.54%, C% to be 52.38%, and H% to be 5.74%, consistent with the theoretical values. The peak pI range was 5.99-7.095, and the specific rotation was 32.3°.
[0466] Radiolabeling and radiochemical purity determination of SDYD03
[0467] Radiochemical purity refers to the percentage of radionuclides in a radioactive sample that exist in a specific chemical form. In this experiment, it refers to the percentage of radioactivity successfully labeled on compound SDYD03 compared to the total radioactivity after purification.
[0468] 1. 68 Ga labeling: 10 μg of compound SDYD03 was added to 100 μL NaOAc (0.25 M) buffer, and then 400 μL 68 GaCl3 solution (0.05M HCl elution 68 Ge- 68 Ga generator), shaken at 100 ° C for 15 min; the crude product was purified by C18 column. Radioactive high performance liquid chromatography was used to determine 68 Radiochemical purity of Ga-SDYD03.
[0469] 2. 177Lu labeling: 15 μg of compound SDYD03 was added to 150 μL of sodium acetate buffer (pH = 4.6), and 20 Mbq of 177 Lu in LuCl3 solution was shaken at 100℃ for 50min; the crude product was purified by C18 column. Radioactive HPLC was used to determine 177 Radiochemical purity of Lu-SDYD03.
[0470] After purification on a C18 column, the 68 Ga / 177 The radiochemical purity of Lu-SDYD03 was determined 68 The radiochemical purity of Ga-SDYD03 is 98%. 177 The radiochemical purity of Lu-SDYD03 was 99% ( FIG. 26 ).
[0471] Stability experiment of SDYD03 radioligand in PBS buffer
[0472] The purpose of this experiment is to test the stability of the radioligand in buffer conditions that simulate the human body. This stability is a prerequisite for further animal studies. If the ligand does not show significant degradation, it indicates that the metal chelation and peptide bond are stable in the buffer.
[0473] 1. 68 Ga-SDYD03: will 68 Ga-SDYD03 was added to a PBS buffer solution at pH 7.4 and incubated at 37° C. for 0.5 hour, 1 hour, and 2 hours. Samples of the mixture were then taken for radioactive HPLC analysis. 68 Stability of Ga-SDYD03 in PBS buffer: 68 After incubation in PBS for 0.5 hours, 1 hour, and 2 hours, the radiochemical purity of Ga-SDYD03 was 96%, 96%, and 95%, respectively ( FIG. 27 ); 68 Ga-SDYD03 is quite stable in PBS buffer.
[0474] 2. 177 Lu-SDYD03: 177 Lu-SDYD03 was added to a PBS buffer solution at pH 7.4, and incubated at 37° C. for 24 hours, 48 hours, and 120 hours. Samples of the mixture were then taken for radioactive HPLC analysis. 177 Stability of Lu-SDYD03 in PBS buffer: 177 After incubation in PBS for 24 hours, 48 hours, and 120 hours, the radiochemical purity of Lu-SDYD03 was 99%, 96%, and 94%, respectively ( FIG. 28 ).177 Lu-SDYD03 is quite stable in PBS buffer.
[0475] Determination of the hydrophilicity and lipophilicity of SDYD03 radioligand
[0476] After purification, 10 μL 68 Ga-SDYD03 was diluted to 500 μL with HEPES buffer (pH = 7.4), then 500 μL of n-octanol was added, vortexed for 30 minutes, and centrifuged. 450 μL of each of the aqueous and organic phases were taken and centrifuged again. Then 100 μL of each of the aqueous and organic phases was taken out and the radioactivity count was measured using a gamma counter, and the octanol / water partition coefficient (Log Do / w) was calculated. 68 The Log Do / w value of Ga-SDYD03 is -1.72±0.04, 177 The Log Do / w value of Lu-SDYD03 is -1.52±0.05.
[0477] Example 6: Synthesis of SDYD04 and Related Radioactivity Experimental Studies
[0478] Synthesis and analysis of SDYD04:
[0479] S1. 4-1 (400 mg) was dissolved in 5 mL of DMF, stirred in an ice bath for five minutes, and then 1.1 eq of HOBt and 1.1 eq of EDC were added. After stirring for five minutes, 4-2 (30 mg) was added, followed by 3.0 eq of NMM, and then the mixture was returned to room temperature and reacted for 2 hours. After the reaction was completed by LC-MS monitoring, DMF was dried and then dissolved in 5 mL of TFA. The mixture was stirred at room temperature for 2.5 h, and then 50 mL of icy ether was added. A large amount of solid precipitated, and the mixture was dried after centrifugation. Reverse phase preparative purification gave 158 mg of 4-3 (yield 60%).
[0480] S2. Dissolve 4-3 (158 mg) and 4-4 (240 mg) in acetonitrile and water (1:1, 5 mL). Add 0.2 M PBS buffer (pH 7.2) (5 mL) under nitrogen. React at room temperature for 1 hour. After completion of the reaction, monitored by LC-MS, reverse phase purification was performed to obtain 210 mg of the desired product, SDYD04 (yield 53%).
[0481] The HPLC purity was 97.69%, as shown in Figure 29. The theoretical molecular weight was 2562.91, but the actual measured [M+3H] / 3 was 1130.3 and [M+4H] / 4 was 848.1, as shown in Figure 30. Elemental analysis showed N% was 12.98%, C% was 50.59%, and H% was 5.57%, consistent with the theoretical values. When the isoelectric point was determined, the product was dissolved in pure water and insoluble matter was found. The supernatant was centrifuged and sampled, but no results were detected. The specific rotation was -22.2°.
[0482] Radiolabeling of SDYD04 and determination of its radiochemical purity
[0483] Radiochemical purity refers to the percentage of radionuclides in a radioactive sample that exist in a specific chemical form. In this experiment, it refers to the percentage of radioactivity successfully labeled on compound SDYD04 compared to the total radioactivity after purification.
[0484] 1. 68 Ga labeling: 10 μg of compound SDYD04 was added to 100 μL NaOAc (0.25 M) buffer, and then 400 μL 68 GaCl3 solution (0.05M HCl elution 68 Ge- 68 Ga generator), shaken at 100 ° C for 15 min; the crude product was purified by C18 column. Radioactive high performance liquid chromatography was used to determine 68 Radiochemical purity of Ga-SDYD04.
[0485] 2. 177 Lu labeling: 20 μg of compound SDYD04 was added to 150 μL of sodium acetate buffer (pH = 4.6), and 20 Mbq of 177 Lu in LuCl3 solution was shaken at 100℃ for 50min; the crude product was purified by C18 column. Radioactive HPLC was used to determine 177 Radiochemical purity of Lu-SDYD04.
[0486] After purification on a C18 column, the 68 Ga / 177 The radiochemical purity of Lu-SDYD04 was determined 68 The radiochemical purity of Ga-SDYD04 is 98%. 177 The radiochemical purity of Lu-SDYD04 was 98% ( FIG. 31 ).
[0487] Stability experiment of SDYD04 radioligand in PBS buffer
[0488] The purpose of this experiment is to test the stability of the radioligand in buffer conditions that simulate the human body. This stability is a prerequisite for further animal studies. If the ligand does not show significant degradation, it indicates that the metal chelation and peptide bond are stable in the buffer.
[0489] 1. 68 Ga-SDYD04: 68 Ga-SDYD04 was added to a PBS buffer solution at pH 7.4 and incubated at 37° C. for 0.5 hour, 1 hour, and 2 hours. Samples of the mixture were then taken for radioactive HPLC analysis. 68 Stability of Ga-SDYD04 in PBS buffer: 68 After incubation in PBS for 0.5 hours, 1 hour, and 2 hours, the radiochemical purity of Ga-SDYD04 was 97%, 97%, and 95%, respectively ( FIG. 32 ). 68 Ga-SDYD04 is quite stable in PBS buffer.
[0490] 2. 177 Lu-SDYD04: 177 Lu-SDYD04 was added to a PBS buffer solution at pH 7.4, and incubated at 37° C. for 24 hours, 48 hours, and 120 hours. Samples of the mixture were then taken for radioactive HPLC analysis. 177 Stability of Lu-SDYD04 in PBS buffer: 177 After incubation in PBS for 24 hours, 48 hours, and 120 hours, the radiochemical purity of Lu-SDYD04 was 97%, 84%, and 63%, respectively ( FIG. 33 ). 177 Lu-SDYD04 is quite stable in PBS buffer.
[0491] Determination of the hydrophilicity and lipophilicity of SDYD04 radioligand
[0492] After purification, 10 μL 68 Ga-SDYD04 was diluted to 500 μL with HEPES buffer (pH = 7.4), then 500 μL of n-octanol was added, vortexed for 30 minutes, and centrifuged. 450 μL of the aqueous phase and 450 μL of the organic phase were taken and centrifuged again. Then 100 μL of each of the aqueous phase and the organic phase were taken out and the radioactivity count was measured using a gamma counter, and the octanol / water partition coefficient (Log Do / w) was calculated. 68 The Log Do / w value of Ga-SDYD04 is -1.63±0.07, 177 The Log Do / w value of Lu-SDYD04 is -1.39±0.03.
[0493] Example 7: Synthesis of SDYD07 and Related Radioactivity Experimental Studies
[0494] Synthesis and analysis of SDYD07:
[0495] S1. Dissolve 7-1 (200 mg) in 20 mL of DMF, add 1.2 eq of HBTU and 3.0 eq of DIPEA, and then add 1.1 eq (211 mg) of 7-2. React at room temperature for 2 hours. After completion of the reaction, monitor the reaction by LC-MS. Add 20 mL of 20% piperidine, concentrate to dryness, wash three times with glacial ether, drain, and separate and purify by reverse phase preparative liquid phase to obtain 190 mg of 7-3 (yield: 64.8%).
[0496] S2. 7-4 (190 mg) was dissolved in 20 mL of DMF, and 1.2 eq of HBTU and 3.0 eq of DIPEA were added, followed by the addition of 1.0 eq (190 mg) of 7-3. The mixture was reacted at room temperature for 2 hours. The reaction was monitored by LC-MS. The DMF was removed by vortexing, and 20 mL of TFA was added. The mixture was stirred at room temperature for 3 minutes. The reaction was monitored by LC-MS. Glacial ether was added to precipitate a large amount of solid, which was centrifuged. The solid was separated and purified by reverse-phase preparative liquid chromatography to obtain 210 mg of 7-5 (yield: 60.9%).
[0497] S3. 7-5 (210 mg) was dissolved in 20 mL of DMF, and 2.0 eq of DIPEA was added, followed by the addition of 1.1 eq (47 mg) of 7-6. The mixture was reacted at room temperature for 2 hours. The reaction was monitored by LC-MS. The DMF was removed by vortexing, and 20 mL of TFA was added. The mixture was stirred at room temperature for 2 hours. The reaction was monitored by LC-MS. Glacial ether was added to precipitate a large amount of solid, which was centrifuged. The solid was separated and purified by reverse phase preparative liquid chromatography to obtain 122.9 mg of 7-7 (yield: 62%).
[0498] S4. 7-8 (300 mg) was dissolved in 20 mL of DMF, and 1.2 eq of DCC and 1.2 eq of HOSu were added, and the reaction was carried out at room temperature for 6 hours. The precipitated solid was removed by filtration, and 1.2 eq (283 mg) of 7-9 and 2 eq of TEA were added to the filtrate, and the reaction was carried out at room temperature for 3 hours. The reaction was completed after monitoring by LC-MS. 20 mL of 20% piperidine was added, the DMF was removed by rotation, and the product was washed twice with ether and dried. The product was separated and purified by reverse phase preparative liquid phase to obtain 243 mg of 7-10 (yield: 58%).
[0499] S5. 7-11 (103 mg) was dissolved in 20 mL of DMF, and 1.2 eq of DCC and 1.2 eq of HOSu were added. The mixture was reacted at room temperature for 6 hours. The precipitated solid was removed by filtration. Then 0.9 eq (243 mg) of 7-10 and 2 eq of TEA were added to the filtrate. The mixture was reacted at room temperature for 3 hours. The reaction was monitored by LC-MS. The DMF was removed by vortexing, and 20 mL of TFA was added. The mixture was stirred at room temperature for 3 minutes. The reaction was monitored by LC-MS. Glacial ether was added to precipitate a large amount of solid, which was centrifuged. The solid was separated and purified by reverse-phase preparative liquid chromatography to obtain 166 mg of 7-12 (yield: 63%).
[0500] S6. 7-7 (216 mg) was dissolved in 20 mL of H2O / ACN = 1:1, 1.0 eq (166 mg) of 7-12 was added, and then 5 mL of 0.2 mol pH = 7.2 PBS Buffe solution was added and reacted at room temperature for 1 hour. The reaction was monitored by LC-MS. The reaction solution was directly separated and purified by reverse phase preparative liquid chromatography to obtain 194.8 mg of SDYD07 (yield: 51%).
[0501] The HPLC purity was 96.86%, as shown in Figure 34; the theoretical molecular weight was 2165.36, and the actual measured [M+3H] / 3 was 722.6 and [M+4H] / 4 was 542.4, as shown in Figure 35; the elemental analysis results showed that N% was 11.78%, C% was 49.73%, and H% was 5.01%, which were consistent with the theoretical values. The main peak PI was 4.809 and the specific rotation was -32.2°.
[0502] Radiolabeling of SDYD07 and determination of radiochemical purity
[0503] Radiochemical purity refers to the percentage of radionuclides in a radioactive sample that exist in a specific chemical form. In this experiment, it refers to the percentage of radioactivity successfully labeled on compound SDYD07 relative to the total radioactivity after purification.
[0504] 1. 68 Ga labeling: 2.3 nmol of compound SDYD07 was added to 100 μL of NaOAc (0.25 M) buffer, and then 400 μL 68 GaCl3 solution (0.05M HCl elution 68 Ge- 68 Ga generator), shaken at 100 ° C for 15 min; the crude product was purified by C18 column. Radioactive high performance liquid chromatography was used to determine 68 Radiochemical purity of Ga-SDYD07.
[0505] 2. 177Lu labeling: 3.5 nmol of compound SDYD07 was added to 130 μL of sodium acetate buffer (pH=5.6), and 37 Mbq of 177 Lu in LuCl3 solution was shaken at 95℃ for 20min; the crude product was purified by C18 column. Radioactive HPLC was used for determination 177 Radiochemical purity of Lu-SDYD07.
[0506] After purification on a C18 column, the 68 Ga / 177 The radiochemical purity of Lu-SDYD07 was determined 68 The radiochemical purity of Ga-SDYD07 is 99%. 177 The radiochemical purity of Lu-SDYD07 was 99% ( FIG. 36 ).
[0507] Stability experiment of SDYD07 radioligand in phosphate buffer
[0508] The purpose of this experiment is to test the stability of the radioligand in buffer conditions that simulate the human body. This stability is a prerequisite for further animal studies. If the ligand does not show significant degradation, it indicates that the metal chelation and peptide bond are stable in the buffer.
[0509] 1. 68 Ga-SDYD07: 68 Ga-SDYD07 was added to a PBS buffer solution at pH 7.4 and incubated at 37° C. for 0.5 hour, 1 hour, and 2 hours. Samples of the mixture were then taken for radioactive HPLC analysis. 68 Stability of Ga-SDYD07 in PBS buffer: 68 After incubation in PBS for 0.5 hours, 1 hour, and 2 hours, the radiochemical purity of Ga-SDYD07 was 99%, 98%, and 98%, respectively ( FIG. 37 ). 68 Ga-SDYD07 is quite stable in PBS buffer.
[0510] 2. 177 Lu-SDYD07: 177 Lu-SDYD07 was added to a PBS buffer solution at pH 7.4, and incubated at 37° C. for 24 hours, 48 hours, and 120 hours. Samples of the mixture were then taken for radioactive HPLC analysis. 177 Stability of Lu-SDYD07 in PBS buffer: 177 After incubation in PBS for 24 hours, 48 hours, and 120 hours, the radiochemical purity of Lu-SDYD07 was 99%, 98%, and 97%, respectively ( FIG. 38 ).
[0511] Determination of the hydrophilicity and lipophilicity of SDYD07 radioligand
[0512] After purification, 10 μL 68 Ga-SDYD07 was diluted to 500 μL with HEPES buffer (pH = 7.4), and then 500 μL of n-octanol was added. The mixture was vortexed for 30 minutes and then centrifuged. 450 μL of each of the aqueous and organic phases were taken and centrifuged again. Then 100 μL of each of the aqueous and organic phases was taken out and the radioactivity count was measured using a gamma counter. The octanol / water partition coefficient (Log Do / w) was calculated. 68 The Log Do / w value of Ga-SDYD07 is -2.94±0.15, 177 The Log Do / w value of Lu-SDYD07 is -2.71±0.15.
[0513] Example 8: Synthesis of SDYD08 and Related Radioactivity Experimental Studies
[0514] Synthesis and analysis of SDYD08:
[0515] S1. 8-1 (300 mg) was dissolved in 20 mL of DMF, and then 1.2 eq of HBTU and 3.0 eq of DIPEA were added, followed by 1.1 eq (142 mg) of 8-2. The mixture was reacted at room temperature for 2 hours. After completion of the reaction, LC-MS was monitored. 20 mL of 20% piperidine was added, the mixture was concentrated to dryness, and the mixture was washed three times with glacial ether. The mixture was drained and purified by reverse phase preparative liquid phase separation to obtain 210 mg of 8-3 (yield: 58%).
[0516] S2. 8-4 (123 mg) was dissolved in 20 mL of DMF, and 1.2 eq of DCC and 1.2 eq of HOSu were added. The mixture was reacted at room temperature for 6 hours. The precipitated solid was removed by filtration. Then 0.9 eq (210 mg) of 8-3 and 2 eq of TEA were added to the filtrate. The mixture was reacted at room temperature for 3 hours. The reaction was monitored by LC-MS. 20 mL of 20% piperidine was added, the DMF was removed by rotation, the mixture was washed twice with ether, and the mixture was dried. The mixture was separated and purified by reverse phase preparative liquid phase to obtain 186 mg of 8-5 (yield: 56%).
[0517] S3. 8-5 (186 mg) was dissolved in 20 mL of DMF, and 2.0 eq of DIPEA was added, followed by the addition of 1.1 eq (29 mg) of 8-6. The mixture was reacted at room temperature for 2 hours. The reaction was monitored by LC-MS. The DMF was removed by vortexing, and 20 mL of TFA was added. The mixture was stirred at room temperature for 2 hours. The reaction was monitored by LC-MS. Glacial ether was added to precipitate a large amount of solid, which was centrifuged. The solid was separated and purified by reverse phase preparative liquid chromatography to obtain 119.8 mg of 8-7 (yield: 67%).
[0518] S4. Dissolve 8-7 (119.8 mg) in 20 mL of H2O / ACN = 1:1, add 1.0 eq (62 mg) of 8-8, and then add 5 mL of 0.2 mol pH = 7.2 PBS Buffe solution and react at room temperature for 1 hour. After the reaction is completed, monitor the reaction by LC-MS. The reaction solution is directly separated and purified by reverse phase preparative liquid chromatography to obtain 121.7 mg of SDYD08 (yield: 67%).
[0519] The HPLC purity was 96.64%, as shown in Figure 39; the theoretical molecular weight was 2763.21, and the actual measured [M+3H] / 3 was 922.0 and [M+4H] / 4 was 691.4, as shown in Figure 40; the elemental analysis results showed that N% was 13.84%, C% was 48.65%, and H% was 5.73%, which were consistent with the theoretical values. The main peak PI was 2.916 and the specific rotation was -24.3°.
[0520] Radiolabeling of SDYD08 and determination of its radiochemical purity
[0521] Radiochemical purity refers to the percentage of radionuclides in a radioactive sample that exist in a specific chemical form. In this experiment, it refers to the percentage of radioactivity successfully labeled on compound SDYD08 compared to the total radioactivity after purification.
[0522] 1. 68 Ga labeling: 3.0 nmol of compound SDYD08 was added to 100 μL of NaOAc (0.25 M) buffer, and then 400 μL of 68 GaCl3 solution (0.05M HCl elution 68 Ge- 68 Ga generator), shaken at 100 ° C for 15 min; the crude product was purified by C18 column. Radioactive high performance liquid chromatography was used to determine 68 Radiochemical purity of Ga-SDYD08.
[0523] 2. 177 Lu labeling: 3.6 nmol of compound SDYD08 was added to 130 μL of sodium acetate buffer (pH=5.6), and 37 Mbq of 177 Lu in LuCl3 solution was shaken at 95℃ for 20min; the crude product was purified by C18 column. Radioactive HPLC was used to determine 177 Radiochemical purity of Lu-SDYD08.
[0524] After purification on a C18 column, the 68 Ga / 177The radiochemical purity of Lu-SDYD08 was determined 68 The radiochemical purity of Ga-SDYD08 is 99%. 177 The radiochemical purity of Lu-SDYD08 was 99% ( FIG. 41 ).
[0525] Stability experiment of SDYD08 radioligand in phosphate buffer
[0526] The purpose of this experiment is to test the stability of the radioligand in buffer conditions that simulate the human body. This stability is a prerequisite for further animal studies. If the ligand does not show significant degradation, it indicates that the metal chelation and peptide bond are stable in the buffer.
[0527] 1. 68 Ga-SDYD08: 68 Ga-SDYD08 was added to a PBS buffer solution at pH 7.4 and incubated at 37° C. for 0.5 hour, 1 hour, and 2 hours. Samples of the mixture were then taken for radioactive HPLC analysis. 68 Stability of Ga-SDYD08 in PBS buffer: 68 After incubation in PBS for 0.5 hours, 1 hour, and 2 hours, the radiochemical purity of Ga-SDYD08 was 99%, 97%, and 96%, respectively ( FIG. 42 ). 68 Ga-SDYD08 is quite stable in PBS buffer.
[0528] 2. 177 Lu-SDYD08: 177 Lu-SDYD08 was added to a PBS buffer solution at pH 7.4, and incubated at 37° C. for 24, 48, and 120 hours. Samples of the mixture were then taken for radioactive HPLC analysis. 177 Stability of Lu-SDYD08 in PBS buffer: 177 After Lu-SDYD08 was incubated in PBS for 24 hours, 48 hours, and 120 hours, its radiochemical purity was 98%, 97%, and 95%, respectively (Figure 43). 177 Lu-SDYD08 is quite stable in PBS buffer.
[0529] Determination of the hydrophilicity and lipophilicity of SDYD08 radioligand
[0530] After purification, 10 μL 68Ga-SDYD08 was diluted to 500 μL with HEPES buffer (pH = 7.4), and then 500 μL of n-octanol was added. The mixture was vortexed for 30 minutes and then centrifuged. 450 μL of the aqueous phase and 450 μL of the organic phase were taken and centrifuged again. Then 100 μL of each of the aqueous phase and the organic phase were taken out and the radioactivity count was measured using a gamma counter. The octanol / water partition coefficient (Log Do / w) was calculated. 68 The Log Do / w value of Ga-SDYD08 is -3.23±0.16, 177 The Log Do / w value of Lu-SDYD08 is -2.82±0.13.
[0531] Example 9: Synthesis of SDYD07-1
[0532] The SDYD07-1 compound was synthesized by the method of Reference Example 7. The synthetic route is as follows:
[0533] Test example:
[0534] The cell lines involved in the cell experiment of this test example include: SUM149PT human breast cancer cell line, HUTU-80 duodenal adenocarcinoma cell line, and U-118MG human brain astrocytoblastoma cell line.
[0535] Each cell line was cultured using the following conditions:
[0536] SUM149PT: Prepare complete culture medium using DMEM high-glucose medium, 10% FBS, and penicillin-streptomycin solution. Culture the cells in a 37°C, 5% CO2 incubator, regularly changing the medium and subculturing the cells. The medium should generally be changed every 2 to 3 days. Observe the growth of the tumor cells under a microscope daily, including cell growth status, adherence to the culture medium, abnormal cell morphology, contamination, and abnormal culture medium color. Subculture the cells when they reach 80% to 90% confluence.
[0537] HUTU-80: Prepare complete culture medium using DMEM high-glucose medium, 10% FBS, and penicillin-streptomycin solution. Culture cells in a 37°C, 5% CO2 incubator, regularly changing the medium and subculturing the cells. The medium should generally be changed every 2 to 3 days. Observe tumor cell growth under a microscope daily, including cell growth status, adherence to the culture medium, abnormal cell morphology, contamination, and abnormal culture medium color. Subculture cells when they reach 80% to 90% confluence.
[0538] U-118MG: Prepare complete culture medium using DMEM high-glucose medium, 10% FBS, and penicillin-streptomycin solution. Culture the cells in a 37°C, 5% CO2 incubator, regularly changing the medium and subculturing the cells. The medium should generally be changed every 2 to 3 days. Observe the growth of the tumor cells under a microscope daily, including cell growth status, adherence to the culture medium, abnormal cell morphology, contamination, and abnormal culture medium color. Subculture the cells when they reach 80% to 90% confluence.
[0539] Cell plating
[0540] When the cell confluence in the cell culture flask reached 80%, the cells were digested and centrifuged, and the supernatant was removed. An appropriate amount of culture medium was added to dilute the culture medium so that each well contained 500 μL of culture medium when the plate was plated. After sufficient pipetting and mixing, the cell suspension was inoculated into a 24-well plate, with 5×10 cells per well. 5 The cells were placed in a cell culture box and continued to grow. When the cells grew to 80%, they could be used for cell experiments.
[0541] Test Example 1 Cell uptake and inhibition test
[0542] (1) The cell uptake test was performed at four incubation time points, namely 15, 30, 60 and 120 minutes. Four groups were set at each time point, namely the no inhibition group, the first single inhibition group (FAP single inhibition group), the second single inhibition group (CXCR4 / GRPR / α v β3 single inhibition group), double inhibition group (FAP inhibitor + CXCR4 / GRPR / α v β3 inhibitor). Three replicate wells were set up for each group at each time point.
[0543] (2) Cells were plated in 24-well plates according to the aforementioned cell plating steps.
[0544] (3) Remove the original culture medium from the 24-well plate and add 400 μL of 100 mg / mL skim milk powder solution to each well for blocking for one hour. Then remove the skim milk powder and add 400 μL of PBS solution to each well for washing three times. Then add 146 μL of culture medium without fetal bovine serum to each well. Next, add 4 μL of cold PBS to each well of the non-inhibition group. For the first single inhibition group, the second single inhibition group, and the double inhibition group, add 2 μL of the non-radioactive labeled first single inhibitor solution and 2 μL of cold PBS, 2 μL of the non-radioactive labeled second single inhibitor solution and 2 μL of cold PBS, 2 μL of the non-radioactive labeled first single inhibitor solution (10 mM), and 2 μL of the non-radioactive labeled second single inhibitor solution (10 mM) to each well according to Table 3 below. Incubate at room temperature for one hour.
[0545] (4) 68 Ga and177 Lu-labeled radioligand was added to culture medium without fetal bovine serum to a concentration of 20 nM. 50 μL of radioligand was added to each well. Each group was incubated for 15, 30, 60, and 120 min.
[0546] (5) After incubation, remove the supernatant and wash three times with 400 μL of PBS solution. Add 200 μL of 1 M NaOH solution to each well for cell lysis. Wait for about 5 minutes. When flocs are observed in the wells, collect the lysed cell solution into a radioimmunoassay tube. Wash each well once with 400 μL of PBS solution and add it to the corresponding radioimmunoassay tubes in sequence.
[0547] (6) The radioactivity in the cells was measured using a γ counter and a histogram was plotted using GraphPad Prism software. The inhibition rate of the inhibition group was calculated as (1-radioactivity counts in the inhibition group / radioactivity counts in the non-inhibition group)*100%.
[0548] For example: FAP single inhibition group inhibition rate = (1-FAP single inhibition group radioactive count / no inhibition group radioactive count) * 100%.
[0549] Table 3 Cellular uptake test groups of each compound
[0550] The experimental results show that;
[0551] SDYD01:FAP single inhibition group and no inhibition group in the first 30 minutes, with the increase of incubation time, SUM149PT cells 68 Ga-SDYD01 uptake subsequently increased, slowly increasing from 30 to 120 minutes before reaching equilibrium. Starting at 30 minutes, cellular uptake in the uninhibited group was higher than in the other groups, particularly at 120 minutes, when cellular uptake in the uninhibited group was significantly higher than in the FAP single inhibition group, the CXCR4 single inhibition group, and the dual inhibition group, with the dual inhibition group exhibiting lower uptake (Figure 44a). The inhibition rates at different time points for the FAP single inhibition group, the CXCR4 single inhibition group, and the dual inhibition group are shown in Figure 44b. These results demonstrate that compound SDYD01 can rapidly and efficiently bind specifically to the CXCR4 protein, rapidly targeting its target and, to a certain extent, specifically binding to fibroblast activation protein.
[0552] SDYD03: Each group slowly increased within 15-120 minutes and then tended to balance. From 15 minutes onwards, the cell uptake results of the non-inhibition group were higher than those of the other three groups; the double inhibition group had lower cell uptake counts than the FAP single inhibition group and the GRPR single inhibition group (Figure 45a). The inhibition rates of the FAP single inhibition group, the GRPR single inhibition group, and the double inhibition group at different time points are shown in Figure 45b. It can be seen that the inhibition rate of the double inhibition group is higher than that of the FAP single inhibition group and the GRPR single inhibition group, indicating that the compound can specifically bind to both FAP and GRPR.
[0553] SDYD04: The trend of change over time in each group remained consistent, with a significant increase in cellular uptake within the first 15 minutes, and uptake reaching a peak at 60 minutes in the non-inhibition group. The uptake of the FAP single inhibition group and the GRPR single inhibition group was comparable at each time point, the dual inhibition group had the lowest cellular uptake, and the non-inhibition group had the highest cellular uptake (Figure 46a). The inhibition rates at different time points in the FAP single inhibition group, the GRPR single inhibition group, and the dual inhibition group are shown in Figure 46b. The results showed that SDYD04 can specifically bind to both FAP and GRPR, and the combination of dual ligands increases the rate of cellular uptake of radioactive compounds.
[0554] SDYD05: The cellular uptake in the non-inhibition group and the FAP single inhibition group increased significantly within 15 minutes, slowly increased from 15 to 120 minutes and then tended to balance. The cellular uptake in the CXCR4 single inhibition group and the double inhibition group increased within 15 minutes, and there was no significant change from 15 to 120 minutes, approaching dynamic equilibrium. From 15 minutes onwards, the cellular uptake in the non-inhibition group was the highest, followed by the FAP single inhibition group, and the double inhibition group had the lowest uptake rate (Figure 47a). The inhibition rates of the FAP single inhibition group, the CXCR4 single inhibition group, and the double inhibition group at different time points are shown in Figure 47b. The results show that the compound SDYD05 can quickly and efficiently bind specifically to the CXCR4 protein, can quickly target the target, and can also specifically bind to the fibroblast activation protein to a certain extent.
[0555] SDYD06: The cell uptake in the non-inhibition group and the FAP single inhibition group increased significantly within 15 minutes, and slowly increased from 15 to 120 minutes and then tended to balance. Within 60 minutes, as the incubation time increased, the cell uptake in the CXCR4 single inhibition group and the double inhibition group slowly increased, and there was no significant change from 60 to 120 minutes, showing a dynamic equilibrium. From 15 minutes on, the cell uptake was ranked from high to low as follows: non-inhibition group, FAP single inhibition group, CXCR4 single inhibition group, and double inhibition group. The results of cell uptake in the non-inhibition group and FAP were similar, and the results of the CXCR4 single inhibition group and the double inhibition group were similar (Figure 48a). The inhibition rates of the FAP single inhibition group, CXCR4 single inhibition group, and double inhibition group at different time points are shown in Figure 48b.
[0556] SDYD07: The cell uptake in each group increased significantly within 15 minutes, and then increased slowly. At 30 minutes, the cell uptake was ranked from high to low as follows: no inhibition group, FAP single inhibition group, integrin α v β3 single inhibition group, double inhibition group (Figure 49a). FAP single inhibition group, integrin α v The inhibition rates of the β3 single inhibition group and double inhibition group at different time points are shown in Figure 49b.
[0557] SDYD08: Cell uptake increased significantly in all groups within 15 minutes, while the non-inhibition group increased slowly from 15 to 30 minutes, increased significantly from 30 to 60 minutes, and showed no significant change from 60 to 120 minutes. v The β3 single inhibition group increased significantly within 15 minutes, and there was no significant change from 15 to 120 minutes, showing a dynamic balance. At 30 minutes, the cellular uptake was ranked from high to low as follows: no inhibition group, FAP single inhibition group, integrin α v β3 single inhibition group, double inhibition group (Figure 50a). FAP single inhibition group, integrated α v The inhibition rates of the β3 single inhibition group and the double inhibition group at different time points are shown in Figure 50b. The results showed that the SDYD08 compound can specifically bind to fibroblast activation protein and integrin α v β3 has good specific targeting effect on these two targets.
[0558] Test Example 2 Cell saturation experiment
[0559] (1) Cell saturation experiment: 8 radiolabeled ligand concentrations were set at intervals within the expected range. Each concentration had 3 groups, namely, no inhibition group, first single inhibition group (FAP single inhibition group), second single inhibition group (CXCR4 / GRPR / α v β3 single inhibition group). Each concentration and each group were set up with three replicate wells.
[0560] (2) Cells were plated in 24-well plates according to the aforementioned cell plating steps.
[0561] (3) Remove the original culture medium from the 24-well plate and add 400 μL of 100 mg / mL skim milk powder solution to each well for one hour. Then remove the skim milk powder and add 400 μL of PBS solution to each well for three washes. Add 146 μL of culture medium without fetal bovine serum to each well. Then, add 4 μL of cold PBS to each well of the non-inhibition group. For the first single inhibition group, the second single inhibition group, and the double inhibition group, add 2 μL of the non-radioactive labeled first single inhibitor solution and 2 μL of cold PBS, 2 μL of the non-radioactive labeled second single inhibitor solution and 2 μL of cold PBS to each well according to Table 4. Incubate at room temperature for one hour.
[0562] (4) Use the marking method described above 68The ligand was radioactively labeled with Ga, and the radioactive ligand system of corresponding concentration was prepared by adding different volumes of culture medium without fetal bovine serum, and 50 μL of the radioactive ligand system of corresponding concentration was added to each well.
[0563] (5) Remove the supernatant and wash three times with 400 μL of PBS solution. Add 200 μL of 1 M NaOH solution to each well to lyse the cells. Wait for about 5 minutes. When flocs are observed in the wells, collect the lysed cell solution into a radioimmunoassay tube. Add 400 μL of PBS solution to each well to wash once, and then add it to the corresponding radioimmunoassay tubes in sequence.
[0564] (6) The radioactivity in the cells was measured using a γ counter, and the equilibrium dissociation constant (K) was obtained by fitting the curve using nonlinear regression analysis using GraphPad Prism software. D ). K D Refers to the drug concentration that causes half of the maximum effect (50% of the receptors are occupied). D The larger the value, the higher the drug concentration required to induce the maximum effect and the smaller the affinity. D The values are shown in Table 5 below.
[0565] The results showed that 68 Ga-labeled SDYD01, SDYD02, SDYD03, SDYD04, SDYD05, SDYD06, SDYD07, and SDYD08 all have smaller K D values, all of which have good binding affinity with the receptor.
[0566] Table 4 Grouping of cell saturation test for each compound
[0567] Table 5 Dissociation constants of each compound in cell saturation test
[0568] Experimental Example 3: Small Animal PET Imaging Experiment and Biodistribution Study
[0569] Eleven NSG mice were harvested to carry subcutaneous transplanted tumors (U87 MG cells), with tumors of approximately 150 mm in size. 3 About 7.4MBq was injected through the tail vein 68 Ga-labeled SDYD01, SDYD02, SDYD03, SDYD04, SDYD05, SDYD06, SDYD07, SDYD08 or SDYD07-1 compound, or 68Ga-labeled FAPI-04 and FAP2286 compounds were used as tracers. Micro PET / CT imaging was performed 30, 60, and 120 minutes after injection. Static images were acquired in 3D mode for 20 minutes. Attenuation-corrected PET / CT fusion images were reconstructed using the OSEM 3D / MAP method. Tumor imaging was observed in each group.
[0570] NSG mice bearing subcutaneous transplanted tumors (U87 MG cells) were divided into three groups, with 11 mice in each group, and injected via the tail vein. 68 Ga-labeled SDYD01, SDYD02, SDYD03, SDYD04, SDYD05, SDYD06, SDYD07, SDYD08 or SDYD07-1 compound, or 68 Ga-labeled FAPI-04 and FAP2286 compounds were used as tracers. 68 Ga-labeled compounds SDYD01, SDYD02, SDYD03, SDYD04, SDYD05, SDYD06, and 68 The mice bearing tumors of the Ga-labeled compounds FAPI-04 and FAP2286 were killed at 30 min, 60 min, and 120 min, respectively. 68 Mice bearing tumors labeled with Ga-labeled compounds SDYD07, SDYD08, and SDYD07-1 were sacrificed at 30, 60, and 90 minutes, respectively. Blood, tumors, and other major organs and tissues were collected, weighed, and radioactivity was measured. Standard uptake values (SUVs) and percent injected dose per gram of tissue (%ID / g) were calculated after correction for radioactive decay. 68 The imaging results and biodistribution data of each Ga-labeled compound as a tracer are shown in Figures 51 to 61, where (a) is the PET / CT imaging result, (b) is the biodistribution result, and (c) is the relative ratio of tumor / normal tissue radioactivity uptake.
[0571] The results showed that the injection 68 Ga-SDYD01, 68 Ga-SDYD02, 68 Ga-SDYD03, 68 Ga-SDYD04, 68 Ga-SDYD05, 68 Ga-SDYD06, 68 Ga-SDYD07, 68The mice bearing Ga-SDYD08 tumors showed significant radioactive uptake at the tumor site. At 30 and 60 minutes, the absolute uptake of radionuclide-labeled compounds at the tumor site reached more than 10% ID / g. Moreover, the radionuclide-labeled compounds were rapidly cleared from the non-tumor site. 68 Ga-FAPI-04, 68 The radioactive deposition at the tumor site of Ga-FAPI-2286-bearing mice was significantly reduced, indicating that the dual-target compound provided by the embodiment of the present invention has better tumor targeting specificity and uptake efficiency, and can be used for radioactive diagnosis and treatment.
[0572] For example, according to FIG57(a), injection 68 Ga-SDYD07, 30min (0.5h) tumor site for 68 The absolute uptake value of Ga-SDYD07 can reach more than 10% ID / g, and can reach 15% ID / g at 60min (1h). At 120min (2h), the absolute uptake value is still around 10% ID / g. However, at 30min and 60min, the tumor site of the tumor-bearing mice 68 The absolute uptake value of Ga-SDYD07-1 was only about 3% ID / g, and the uptake of the tumor decreased significantly after 60 minutes. 68 Ga-SDYD07 compared to 68 Ga-SDYD07-1 has a higher tumor uptake and a longer tumor retention time. It is expected that after SDYD07 is labeled with therapeutic radionuclides, the tumor treatment effect will be better. As can be seen from Figures 57(b) and (c), 68 At 60 minutes after the administration of Ga-SDYD07, the radioactive uptake levels of other non-target organs were significantly reduced and far lower than that of tumors, and the target / non-target ratio increased significantly, indicating that 68 Ga-SDYD07 has excellent tumor-specific uptake and low non-specific uptake level; in comparison, 68 Ga-SDYD07-1 showed high nonspecific uptake in the kidney and liver, indicating that 68 Ga-SDYD07 can provide better PET-CT image quality and has good diagnostic prospects.
[0573] Although the present invention has been described in detail above using general explanations, specific embodiments, and experiments, it will be apparent to those skilled in the art that modifications and improvements may be made based on the present invention. Therefore, such modifications and improvements, which do not depart from the spirit of the present invention, are intended to be within the scope of protection claimed herein.
Claims
1. A compound having a structure represented by formula (I), or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt thereof, in, R 1 , R 3 and R 4 are each independently selected from a bond, -U 1 -G 1 -A 1 -LA 2 -G 2 -U 2 - or heteroalkylene, R 1 , R 3 and R 4 At least one of them is -U 1 -G 1 -A 1 -LA 2 -G 2 -U 2 -;or for R 3 and R 4 At least one of them is -U 1 -G 1 -A 1 -LA 2 -G 2 -U 2 -; L is or a bond, n1, n2, n3 and n4 are each independently 0, 1, 2 or 3; A 1 and A 2 are each independently selected from a bond, -C(=O)NH-, -NHC(=O)- or -C(=O)-; G 1 and G 2 Each independently selected from a bond, a heteroalkylene or z1 and z2 are each independently selected from 0, 1, 2 or 3; U 1 and U 2 are each independently selected from a bond, Each t1 is independently selected from 1, 2, 3 or 4; U 1 , G 1 , A 1 , L, A 2 , G 2 and U 2 Not a key at the same time; m1, m2, m3 and m4 are each independently selected from 0, 1, 2, 3, 4 or 5; Q 1 , Q 2 and Q 3 One of the two is a chelating group, another is a group targeting a FAP receptor, and the other is a group targeting other receptors, wherein the other receptors are selected from the group of CXCR4 receptor, GRPR receptor or α v β3 receptor; Optionally, the heteroalkylene group is an alkylene group containing at least one sulfur atom; or Optionally, the heteroalkylene group is -(CH2) q -S-(CH2) p -, p and q are each independently selected from 0, 1, 2, 3, 4 or 5, and p and q are not 0 at the same time.
2. The compound according to claim 1, characterized in that (1) having a structure represented by formula (I'-A), or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof: Each symbol has the same meaning as in formula (I), Preferably, Q 1 Q is a group targeting FAP receptor. 2 To target other receptors such as CXCR4 receptor, α v β3 receptor or GRPR receptor group, Q 3 is a chelating group; or Q 2 Q is a group targeting FAP receptor. 1 To target other receptors such as CXCR4 receptor, α v β3 receptor or GRPR receptor group, Q 3 is a chelating group; Preferably, R 1 and R 3 One of the following: 1 -G 1 -A 1 -LA 2 -G 2 -U 2 -, another selected from a key, U 1 or G 1 ; L is n1, n2, n3 and n4 are each independently 0, 1, 2 or 3; A 1 and A 2 are each independently selected from a bond, -C(=O)NH-, -NHC(=O)- or -C(=O)-; G 1 and G 2 are each independently selected from a bond, -(CH2) q -S-(CH2) p -,or z1 and z2 are each independently selected from 0, 1, 2 or 3; p and q are each independently selected from 0, 1, 2, 3, 4 or 5, and p and q are not 0 at the same time; U 1 and U 2 are each independently selected from a bond, Each t1 is independently selected from 1, 2, 3 or 4; m1, m2, m3 and m4 are each independently selected from 0, 1, 2, 3, 4 or 5; or (2) The compound has the structure shown in Formula I'-B, or its stereoisomers, tautomers, or pharmaceutically acceptable salts: Among them, Q 1 Q is a group targeting FAP receptor. 2 For targeting the other receptors such as GRPR receptor, Q 3 is a chelating group; or Q 2 Q is a group targeting FAP receptor. 1 For targeting the other receptors such as GRPR receptor, Q 3 is a chelating group; R 1 and R 3 One of the following: 1 -G 1 -A 1 -LA 2 -G 2 -U 2 -, another selected from a bond, -(CH2) q -S-(CH2) p -、U 1 or G 1 ; p and q are each independently selected from 0, 1, 2, 3, 4 or 5, and p and q are not 0 at the same time; L is n1, n2, n3 and n4 are each independently 0, 1, 2 or 3; A 1 and A 2 are each independently selected from a bond, -C(=O)NH-, -NHC(=O)- or -C(=O)-; G 1 and G 2 Each independently selected from a bond or z1 and z2 are each independently selected from 0, 1, 2 or 3; U 1 and U 2 are each independently selected from a bond, Each t1 is independently selected from 1, 2, 3 or 4; m1, m2 and m3 are each independently selected from 0, 1, 2, 3, 4 or 5; or (3) The compound has a structure as shown in Formula I'-C, or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof; The definitions of the symbols are the same as those in Formula I. Preferably, Q 1 Q is a group targeting FAP receptor. 3 To target other receptors such as α v β3 receptor group, Q 2 is a chelating group; or Q 3 Q is a group targeting FAP receptor. 1 To target other receptors such as α v β3 receptor group, Q 2 is a chelating group; Preferably, R 1 and R 4 One of the following: 1 -G 1 -A 1 -LA 2 -G 2 -U 2 -, another selected from a bond, -(CH2) q -S-(CH2) p -、U 1 or G 1 ; p and q are each independently selected from 0, 1, 2, 3, 4 or 5, and p and q are not 0 at the same time; or for R 4 For -U 1 -G 1 -A 1 -L-A 2 -G 2 -U 2 -; L is n1, n2, n3 and n4 are each independently 0, 1, 2 or 3; A 1 and A 2 are each independently selected from a bond, -C(=O)NH-, -NHC(=O)- or -C(=O)-; G 1 and G 2 Each independently selected from a bond or z1 and z2 are each independently selected from 0, 1, 2 or 3; U 1 and U 2 are each independently selected from a bond, Each t1 is independently selected from 1, 2, 3 or 4; m1, m2 and m3 are each independently selected from 0, 1, 2, 3, 4 or 5.
3. The compound according to any one of claims 1 to 2, characterized in that The compound has a structure shown in Formula I-2, Formula I-1, I-3, I-4, I-5, I-6, I-7 or I-8, or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof: In Formula I-2, Q 1 , Q 2 , Q 3 The definition is the same as that in formula (I); preferably, Q 1 is a group targeting FAP receptor; Q 2 is a group targeting other receptors such as CXCR4 receptor; Q 3 is a chelating group; or Q 1 is a group targeting other receptors such as CXCR4 receptor; Q 2 is a group targeting FAP receptor; Q 3 is a chelating group; In formulas I-1, I-3 and I-4, Q 1 , Q 2 , Q 3 The definition is the same as that in formula (I); preferably, Q 1 For groups targeting other receptors such as the CXCR4 receptor, Q 2 Q is a group targeting FAP receptor. 3 is a chelating group; or Q 2 Q is a group targeting FAP receptor. 1 For groups targeting other receptors such as the CXCR4 receptor, Q 3 is a chelating group; In formula I-5, Q 1 , Q 2 , Q 3 The definition is the same as that in formula (I); preferably, Q 1 is a group targeting other receptors such as GRPR receptor; Q 2 is a group targeting FAP receptor; Q 3 is a chelating group; or Q 2 is a group targeting other receptors such as GRPR receptor; Q 1 is a group targeting FAP receptor; Q 3 is a chelating group; In formula I-6, Q 1 , Q 2 , Q 3 The definition is the same as that in formula (I); preferably, Q 1 is a group targeting FAP receptor; Q 2 is a group targeting other receptors such as GRPR receptor; Q 3 is a chelating group; or Q 2 is a group targeting FAP receptor; Q 1 is a group targeting other receptors such as GRPR receptor; Q 3 is a chelating group; In formulas I-7 and I-8, Q 1 , Q 2 , Q 3 The definition is the same as that in formula (I); preferably, Q 1 is a group targeting FAP receptor; Q 2 is a chelating group; Q 3 To target other receptors such as α v β3 receptor group; or Q 3 is a group targeting FAP receptor; Q 2 is a chelating group; Q 1 To target other receptors such as α v β3 receptor group.
4. The compound according to any one of claims 1 to 3, characterized in that The compound has a structure shown in formula II-A, II-B, II-C1, II-C2 or II-D or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof: In II-A, the definitions of the symbols are the same as those in Formula I. Preferably, Q 1 is a group targeting the FAP receptor; In II-B, the definitions of the symbols are the same as those in Formula I. Preferably, Q 2 is a group targeting the FAP receptor; In II-C1 and II-C2, the definitions of the symbols are the same as those in Formula I. Preferably, Q 1 is a group targeting FAP receptor; Q 2 is a chelating group; In II-D, the definitions of the symbols are the same as those in Formula I. Preferably, Q 1 A group that targets the FAP receptor.
5. The compound according to any one of claims 1 to 3, characterized in that The compound has a structure shown in formula III-1 or III-2 or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof: Wherein, the definitions of the symbols are the same as those in Formula I; preferably, Q 2 A group that targets the FAP receptor.
6. The compound according to claim 1, or its stereoisomer, tautomer, or pharmaceutically acceptable salt, wherein the compound has a structure shown in Formula V: in, Each U 1 are each independently selected from a bond, Each t1 is independently selected from 1, 2, 3 or 4; m1, m2, m3 and m4 are each independently selected from 0, 1, 2, 3, 4 or 5; y is an integer selected from 3 to 10; Q 1 For the group targeting FAP receptor, Q 2 is a chelating group, Q 3 To target α v β3 receptor group. Preferably, Q 1 Selected from:
7. The compound according to any one of claims 1 to 6, characterized in that The group targeting the FAP receptor is the structure shown in II-1: M 1 、M 2 、M 3 、M 4 、M 5 、M 6 、M 7 are independently selected from a bond, -O-, -CH2-, -NR 8 -, -C(=O)-, -C(=S)-, -C(=NH)R 8 -、-CHR 8 -and-C(R 8 )2-, provided that the two Os are not directly adjacent to each other; M 1 、M 2 、M 3 、M 4 、M 5 、M 6 、M 7 At most 4 of them are keys at the same time; R 6 and R 7 are independently selected from -H, -OH, halogen, C 1-6 Alkyl, -OC 1-6 Alkyl, -SC 1-6 alkyl; R 5 is selected from -H, -CN, -B(OH)2, -C(=O)-alkyl, -C(=O)-aryl-, -C=CC(=O)-aryl, -C=CS(=O)2--Ar-, -C(=O)OH, -S(=O)2OH, -S(=O)2NH2, -P(=O)(OH)2 and 5-tetrazolyl; R 8 Selected from -H, C 1-6 Alkyl, -OC 1-6 Alkyl, -SC 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Heteroalkenyl, C 5-6 Cycloalkenyl, C 4-6 Cycloheteroalkenyl, C 2-6 Alkynyl, C 6-10 Aryl and C 6-10 Aryl C 1-6 Alkyl, the C 1-6 The alkyl group is optionally substituted by 1 to 3 substituents selected from -OH, oxygen, halogen generation; Ring W is selected from naphthyl, 5-10 membered azaaryl.
8. The compound according to claim 7, characterized in that -M 1 -M 2 -M 3 -M 4 -M 5 -M 6 -M 7 - is -C(=O)-CH2-NR 8 -C(=O)-; and / or R 6 and R 7 independently selected from -H or F; and / or Ring W is quinolyl; preferably, ring W is 4-quinolyl.
9. The compound according to claim 7 or 8, characterized in that for 10. The compound according to any one of claims 1 to 9, characterized in that The group targeting the FAP receptor is the structure shown in II-2: R 9 is an alkyl acyl group; R 10 , R 11 Each independently selected from H or CH3; p1 is selected from 0 or 1; p2 is selected from 1 or 2; XA 2 , Xaa 3 , Xaa 4 , Xaa 5 and Xaa 6 Each independently selected from conventional amino acid residues and unconventional amino acid residues; Preferably, XA 2 for R 12 , R 13 , R 14 Each independently selected from C 1-2 alkyl, carboxyl and H, wherein the C 1-2 The alkyl group is optionally substituted with one or two radicals selected from -OH, NH2, halogen, C 5-7 Substitution of cycloalkyl groups; The 3- and 4-positions of are optionally substituted by one or two substituents selected from methyl, OH, NH2 and F; q1 is selected from 0, 1 or 2; q2 is selected from 1, 2 or 3; q3 is selected from 1 or 2; Xaa 3 Yes X 1 Selected from CH2, CF2, CHR 16 , S, O and NH; R 15 is H, methyl, OH, NH2 or F, R 16 is methyl, OH, NH2 or F; Xaa 4 Yes R 17 is methyl or H; R 18 is selected from H, -OH, -C(=O)OH, -(C=O)NH2, X 2 and -NH-C(=O)-X 2 , where X 4 Selected from C 1-6 Alkyl, phenyl and C 5-6 heteroaryl, and X 2 Optionally substituted with one or two substituents selected from methyl, C(═O)NH 2 , halogen, NH 2 and OH; q4 is selected from 1, 2 or 3; wherein optionally, one or two hydrogen atoms of the 1, 2 or 3 CH2 groups are each and independently methyl, ethyl, phenyl or C 5-6 Heteroaryl substitution, Xaa 5 Yes R 19 Selected from OH and NH2; q5 is selected from 1, 2 or 3; XA 6 An amino acid residue selected from aromatic L-α-amino acids and heteroaromatic L-α-amino acids.
11. The compound according to any one of claims 1 to 10, characterized in that The group targeting the FAP receptor is: The group targeting the CXCR4 receptor is selected from: The targeting α v The groups of β3 receptors are: The group targeting the GRPR receptor is:
12. The compound according to any one of claims 1 to 11, characterized in that The chelating group is selected from 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA), 1,4,7,10-tetraazacyclododecane, 1-(pentanedioic acid)-4,7,10-triacetic acid (DOTAGA), 1,4,7-triazacyclononane triacetic acid (NOTA), 1,4,7-triazacyclononane-N-pentanedioic acid-N',N"-diacetic acid (NODAGA), 1,4,7-triazacyclononane-1,4-diacetic acid-methylphenylacetic acid (NODA-MPAA), bis(2-hydroxybenzyl)ethylenediaminediacetic acid (HBED), 4,11-bis-(carboxymethylmethyl)-1,4,8,11-tetraazabicyclo[6.6.2]-hexadecane (CB-TE2A), deferoxamine (DFO) or a group derived from hexadentate tris(3,4-hydroxypyridone) (THP).
13. The compound according to any one of claims 1 to 12, characterized in that The chelating group is one of the following groups: Preferably, the chelating group is 14. The compound according to any one of claims 1 to 13, characterized in that The compound is selected from the following structures or stereoisomers, tautomers, and pharmaceutically acceptable salts thereof:
15. A radionuclide-labeled compound, which is obtained by labeling the compound according to any one of claims 1 to 14 with a radionuclide.
16. The compound according to claim 15, characterized in that The radionuclide is selected from 18 F. 51 Cr, 67 Ga, 68 Ga, 111 In, 99m Tc, 186 Re, 188 Re, 139 La, 140 La, 175 Yb, 153 Sm, 166 Ho, 88 Y. 90 Y. 149 Pm, 165 Dy, 169 2. 177 Lu, 47 Sc, 142 Pr, 159 Gd, 212 Bi, 213 Bi, 72 As, 72 Se, 97 Such as 109 Pd, 105 Rh, 101m Rh, 119 Sb, 128 8. 123 I. 124 I. 131 I. 197 Hg, 211 At 151 Eu, 153 Eu, 169 Eu, 201 Tl, 203 Pb, 212 Pb, 64 Cu, 67 Cu, 188 Re, 186 Re, 198 Au, 225 Ac, 227 Th and 199 Ag.
17. The compound according to claim 15 or 16, characterized in that The radionuclide-labeled compound is selected from:
18. A pharmaceutical composition comprising or consisting of at least one compound according to any one of claims 1 to 17 and optionally a pharmaceutically acceptable carrier and / or excipient, and optionally a pharmaceutically acceptable carrier and / or excipient.
19. A compound according to any one of claims 1 to 17 or a pharmaceutical composition according to claim 18 for use in the diagnosis or treatment of a disease characterized by FAP, CXCR4, GRPR, α v Use or method in a disease characterized by abnormal expression of one or both of β3; Optionally, the disease is characterized by abnormal expression of one or both of FAP and CXCR4; Optionally, the disease is characterized by abnormal expression of one or both of FAP and GRPR; Optionally, the disease is characterized by FAP and α v The abnormal expression of one or both of β3 is characteristic; Preferably, the disease is selected from cancer, chronic inflammation, atherosclerosis, fibrosis, tissue remodeling and scar disease, preferably, the cancer is selected from breast cancer, pancreatic cancer, small intestine cancer, colon cancer, rectal cancer, lung cancer, head and neck cancer, ovarian cancer, hepatocellular carcinoma, esophageal cancer, hypopharyngeal cancer, nasopharyngeal cancer, laryngeal cancer, myeloma cells, bladder cancer, cholangiocarcinoma, clear cell renal carcinoma, neuroendocrine tumors, carcinogenic osteomalacia, sarcoma, CUP (cancer of unknown primary), thymic carcinoma, glioma, glioma, astrocytoma, cervical cancer and prostate cancer.
20. A kit comprising or consisting of a compound according to any one of claims 1 to 17 or a pharmaceutical composition according to claim 18.
Citation Information
Patent Citations
Conjugates of cell binding molecules with cytotoxic agents
US20200172480A1
Antibody construct conjugates
WO2018227023A1
Cross-linked pyrrolobenzodiazepine dimer (PBD) derivative and its conjugates
WO2020006722A1
Chelator compositions for radiometals and methods of using same
WO2021168567A1
Conjugates of a cell-binding molecule with camptothecin analogs
WO2021212638A1
